

13 MAY 2006

PI 1130793

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office


February 19, 2004

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM
THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK
OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT
APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A
FILING DATE.

APPLICATION NUMBER: 60/428,335

FILING DATE: November 22, 2002

RELATED PCT APPLICATION NUMBER: PCT/US03/37200



By Authority of the
COMMISSIONER OF PATENTS AND TRADEMARKS




N. WILLIAMS
Certifying Officer

PRIORITY
DOCUMENT

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

BEST AVAILABLE COPY

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).

Express Mail Lab IN .

EV 034637556 US

INVENTOR(S)

Given Name (first and middle [if any])	Family Name or Surname	Residence (City and either State or Foreign Country)
Mark H. Xue-Ping Michael H.	Kaplan Wang Dosik	Merrik, New York Port Washington, New York East Seatauket, New York

 Additional inventors are being named on the _____ separately numbered sheets attached hereto**TITLE OF THE INVENTION (500 characters max)****ELF3 GENE COMPOSITIONS AND METHODS**

Direct all correspondence to:

CORRESPONDENCE ADDRESS Customer Number
Place Customer Number
Bar Code Label here

OR

Type Customer Number here

 Firm or
Individual Name

Elie H. Gendloff, Alan Miller, or Craig J. Arnold

Address

Amster, Rothstein & Ebenstein

Address

90 Park Avenue

City

New York

State

New York

ZIP

10016

Country

USA

Telephone

212-697-5995

Fax

212-286-0854

ENCLOSED APPLICATION PARTS (check all that apply) Specification Number of Pages

102

 CD(s), Number
 Drawing(s) Number of Sheets

19

 Other (specify)specification cover page, cover
letter and return receipt postcard Application Data Sheet. See 37 CFR 1.76**METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT** Applicant claims small entity status. See 37 CFR 1.27.FILING FEE
AMOUNT (\$) A check or money order is enclosed to cover the filing fees

01-1785

 The Commissioner is hereby authorized to charge filing

\$80.00

fees or credit any overpayment to Deposit Account Number:

 Payment by credit card. Form PTO-2038 is attached.

The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.

 No. Yes, the name of the U.S. Government agency and the Government contract number are: _____

Respectfully submitted,

SIGNATURE

Date 11/22/2002

TYPED or PRINTED NAME Elie H. Gendloff

REGISTRATION NO.
(if appropriate)
Docket Number:

44,704

TELEPHONE 212-697-5995

50425/143

USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT

This collection of information is required by 37 CFR 1.51. The information is used by the public to file (and by the PTO to process) a provisional application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the complete provisional application to the PTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Box Provisional Application, Assistant Commissioner for Patents, Washington, D.C. 20231.



11/22/02

11/25-02

A/pe

AMSTER, ROTHSTEIN & EBENSTEIN

MORTON AMSTER
JESSE ROTHSTEIN (RETIRED)
DANIEL S. EBENSTEIN
PHILIP H. GOTTFRIED
MICHAEL J. BERGER
NEIL M. ZIPKIN
ANTHONY F. LO CICERO
KENNETH P. GEORGE
ABRAHAM KASDAN, PH.D.
IRA E. SILFIN
CHESTER ROTHSTEIN
CRAIG J. ARNOLD

SENIOR COUNSEL
CHARLES R. MACEDO
MARK J. ROSENBERG
KENNETH M. BERNSTEIN

OF COUNSEL
JERRY D. DAINOW

ATTORNEYS AT LAW
PATENTS • TRADEMARKS • COPYRIGHTS
90 PARK AVENUE
NEW YORK, NEW YORK 10016
TELEPHONE: (212) 697-5995
FACSIMILE: (212) 286-0854

NEAL L. ROSENBERG
DENISE A. LINDENAUER
NANCY M. DODDERIDGE
PATRICK BOLAND*
TREBOR LLOYD
JOSEPH M. CASINO
JOHN S. ECONOMOU
MICHAEL V. SOLOMITA
HOLLY PEKOWSKY
MICHAEL P. KENNEY
MARION P. METELSKI*
MAX VERN
DANA R. METES
KARL J. KOLBINGER

BRIAN A. COMACK
RICHARD S. MANDARO
NATALIE BOGDANOS
MARC J. JASON
ELIE H. GENDLOFF, P.C.
DAVID MITNICK
CHARLES W. RATH
BERNARD MAISTER, M.
PREETHI SEKHARAN
DAVID A. BOAG
KAREN J. BERNSTEIN
JAMEL OESSER-SWEAT*

*NOT ADMITTED IN NEW YORK

November 22, 2002

via Express Mail

Commissioner for Patents
Washington, DC 20231

Box: PROVISIONAL PATENT APPLICATION

Re: Rule 1.53(c) Provisional Patent Application Claiming Small Entity Status
 Title: ELF3 GENE COMPOSITIONS AND METHODS
 Inventors: Mark H. Kaplan, Xue-Ping Wang and Michael H. Dosik
 Our File: 50425/143

Dear Sir:

Pursuant to 37 C.F.R. §1.53(c), enclosed please find the following documents for filing with the above-identified provisional application in the names of Mark H. Kaplan, Xue-Ping Wang and Michael H. Dosik, entitled ELF3 GENE COMPOSITIONS AND METHODS, comprising the following:

1. Provisional Application For Patent Cover Sheet (Form PTO/SB/16) (1 page);
2. Provisional patent application, including: application cover page (1 page), specification (88 pages), claims (13 pages), abstract (1 page), and drawings (19 sheets); and
3. Amster, Rothstein & Ebenstein check in the amount of \$80.00 to cover the provisional application filing fee for small entity status; and

221190.1

10997 U.S. PRO
60/42835

Commissioner for Patents
Washington, DC 20231
Box Provisional Patent Application

-2-

November 22, 2002


4. Return receipt postcard.

Please acknowledge receipt of the enclosed papers by stamping the enclosed postcard and returning the same to us.

Respectfully submitted,

AMSTER, ROTHSTEIN & EBENSTEIN
Attorneys for Applicant
90 Park Avenue
New York, New York 10016
(212) 697-5995

Dated: November 22, 2002
New York, New York

By: 
Elie H. Gendloff
Registration No. 44,704

AR&E Docket No. 50425/143

New U.S. Provisional Patent Application (Small Entity Status)

Title: **ELF3 GENE COMPOSITIONS AND METHODS**

Inventors: **Mark H. Kaplan, Xue-Ping Wang, and Michael H. Dosik**

Express Mail EV 034637556 US

ELF3 GENE COMPOSITIONS AND METHODS

Background

(1) Field of the Invention

5 The present invention generally relates to methods and compositions useful for determining whether a patient has cancer or is at risk for cancer. More specifically, the invention relates to ELF3 gene compositions that are associated with cancer, particularly breast cancer, and methods using those compositions in cancer diagnosis.

10 10 (2) Description of the Related Art

References cited

Al-sumidaie A.M., Leinster S.J., Hart C.A., Green C.D., and McCarthy K. Particles with properties of retroviruses in monocytes from patients with breast cancer. *Lancet* 1:5-9, 1988.

15 Altschul, S.F., Gish, W., Miller, W., Myers, E.W. and Lipman, D.J. Basic local alignment search tool. *J. Mol. Biol.* 215:403-410, 1990.

Altschul, S.F., Madden, T.L., Schäffer, A.A., Zhang, J., Zhang, Z., Miller, W. and Lipman, D.J. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. *Nucleic Acids Res.* 25:3389-3402, 1997.

20 Andersson I. Breast cancer screening in Malmo. *Recent Results Cancer Res.* 90:114-6, 1984

Andreoli, J.M., Jang, S.I., Chung, E., Coticchia, C.M., Steinert, P.M., and Markova, N.G. The expression of a novel, epithelial-specific ets transcription factor is restricted to the most differentiated layers in the epidermis. *Nucleic*

25 *Acids Res.* 25: 4287-4295, 1997.

Ausubel M.F., Brent R., Kingston E.R., Moore D.D., Seidman J.G., Smith A.J., Struhl K. *Current Protocols in Molecular Biology* pp. Unit 4.1 Preparation of Cytoplasmic RNA from Tissue Culture Cells, John Wiley & Son Inc., 1995.

Barnes D.M., Bartkova J., Camplejohn R.S., Gullick W.J., Smith P.J., and Millis R.R. Overexpression of the c-erbB-2 oncoprotein: Why does this occur more frequently in ductal carcinoma *in situ* than in invasive mammary carcinoma and is this of prognostic significance? *Eur J Cancer* 28:644-648, 1992.

Beghini, A., Ripamonti, C.B., Peterlongo, P., Roversi, G., Cairoli, R., Morra, E. and Larizza, L. RNA hyperediting and alternative splicing of hematopoietic cell phosphatase (PTPN6) gene in acute myeloid leukemia. *Hum. Mol. Genet.* 22:2297-2304, 2000.

Bonnet M., Guinebretiere J.-M., Kremmer E., Grunewald V., Benhamou E., Contesso G. and Joab I. Detection of Epstein-Barr Virus in invasive breast cancers. *J Natl Cancer Inst* 91:1376-1381, 1999.

Bittner J.J. The milk influence of breast cancer in mice *Science* 95: 462-463, 1942

Brembeck F.H., Opitz O.G., Libermann T.A., and Rustgi A.K. Dual function of the epithelial specific ets transcription factor, ELF3, in modulating differentiation. *Oncogene* 19: 1941-1949, 2000

Chang, C-H., Scott, G.K., Kuo, W-L., Xiong, X., Suzdaltseva, Y., Park, J.W., Sayre, P., Erny, K., Collins, C., Gray, J.W., and Benz, C.C. ESX: A Structurally unique Ets overexpressed early during human breast tumorigenesis. *Oncogene*, 14: 1617-1622, 1997.

Chang, C-H., Scott, G.K., Baldwin, M. A. and Benz, C.C. Exon 4-encoded acidic domain in the epithelium-restricted Ets factor, ESX, confers potent transactivating capacity and binds to TATA-binding protein (TBP). *Oncogene*, 18: 3682-3695, 1999.

Chang J., Lee C., Hahn K.-B., Youngsuk Y., Choi S.-G., and Kim S.-J. Over-expression of ERT (ESX/ESE/ELF3), an ets-related transcription factor,

-3-

induces endogenous TGF- β signaling pathway in Hs578t human breast cancer cells. *Oncogene* 19:151-154, 2000.

Chang, Y., Cesarman, E., Pessin, M.S., Lee, F., Culpepper, J., Knowles, M.D. and Moore, P.S. Identification of herpesvirus-like DNA sequences in AIDS-5 associated Kaposi's sarcoma. *Science* 266: 1865-1869, 1994.

Cheung P., Ellison K.S., Verity R., and Smiley J.R. Herpes Simplex virus ICP27 induces cytoplasmic accumulation of unspliced polyadenylated α -Globin pre-mRNA in infected He La cells. *J. Virology* 74:2913-2919, 2000

Choi, S.G., Yi, Y., Kim, Y.S., Kato, M., Chang, J., Chung, H-W., Hahn, K-10 B., Yang, H-K., Rhee, H.H., Bang, Y-J. and Kim, S-J. A novel ets-related transcription factor, ERT/ESX/ESE-1, regulates expression of the transforming growth factor-beta type II receptor. *J. Biol. Chem.* 273: 110-117, 1998.

Cooper, D.L. Retention of CD44 introns in bladder cancer: understanding the alternative splicing of Pre-mRNA opens new insights into the 15 pathogenesis of human cancers. *J. Path.* 177:1-3, 1995

Cramer, P., Srebrow, A., Kadener, S., Werbajh, S., De La Mata, M., Melen, G., Nogues, G. and Kornblith, A.R. Coordination between transcription and pre-mRNA processing. *FESE Let.* 498:179-182, 2001.

Cullen B.R. Retroviruses as Model Systems for the Study of Nuclear RNA 20 Export Pathways. *Virology* 249:203-210, 1998

Darnell, J., Lodish, H. and Baltimore, D. RNA synthesis and processing in eukaryotes. Chapter 8, pp. 261-313 in *Molecular Cell Biology* 2nd ed. Scientific American Books Inc. 1997.

Don, R.H., Cox, P.T., Wainwright, B.J., Baker, K. and Mattick, J.S. 25 'Touchdown' PCR to circumvent spurious priming during gene amplification. *Nucleic Acids Res.* 19: 4008, 1995.

Ellison K.S., Rice S.A., Verity R., and Smiley J.R. Processing of α -Globin and ICP0 mRNA in cells infected with Herpes Simplex virus type 1 ICP27 Mutants. *J. Virology* 74:7307-7319, 2000.

Fan H. Retroviruses and Their role in Cancer. Ch. 7, Vol. 3 The Retroviridae. Plenum Press, New York and London pg. 344-7, 1994.

Favaro JP, and Arrigo S.J. Characterization of Rev Function Using Subgenomic and Genomic constructs in T and COS Cells. *Virology* 228:29-38, 5 1997.

Flint S.J., Enquist L.W., Krug R.M, Racaniello V.R, and Skalka A.M. Processing of viral pre-mRNA. Chapter 10, pp. 353-358 in *Principles of Virology: Molecular Biology, Pathogenesis and Control*. ASM Press, Washington D.C., 2000.

10 Fluck M.M., Haslam S.Z. Mammary tumors induced by polyomavirus. *Breast Cancer Res.* 39:45-56, 1996.

Fonseca R, Hartmann LC, Petersen IA, Donohue JH, Crotty TB, Gisvold JJ. Ductal Carcinoma In Situ of the Breast. *Ann Intern Med* 127:1013-1022, 1997.

15 Gallo R.C., Salahuddin S.Z., Popovic M., Shearer G.M., Kaplan M., Haynes B.F., Palker T.J., Redfield R., Oleske J., Safai B, White G., Foster P., and Markham P.D. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. *Science* 224:500-503, 1984.

20 Gazdar A.F., Kurvari V., Virmani A., Gollahon L., Sakaguchi M., Westerfield M., Kodagoda D., Stasny V., Cunningham H.T., Wistuba I.I., Tomlinson G., Tonk V., Ashfaq R., Leitch A.M., Minna J.D., and Shay J.W. Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. *Int. J. Cancer* 78: 766-774. 1998.

25 Gish, W. and States, D.J. Identification of protein coding regions by database similarity search. *Nature Genet.* 3:266-272, 1993.

Goodison, S., Yoshida, K., Churchman, M., and Tarin D. Multiple intron retention occurs in tumor cell CD44 mRNA processing. *Am. J. Pathol.* 153:1221-1228, 1998.

-5-

Guldberg, P., thor Straten, P., Ahrenkiel, V., Seremet, T. Kirkin, A. F. and Zeuthen, J. Somatic mutation of the Peutz-Jeghers syndrome gene, LKB1/STK11, in malignant melanoma. *Oncogene* 18:1777-1780, 1999

Hastings M.L, Krainer A.R. Pre-mRNA splicing in the new millennium.

5 Curr Opin Cell Biol (United States) 13:302-9, 2001.

Hellwinkel, O.J-C., Holterhus, P-M., Struve, D., Marschke, C., Homburg, N. and Hiort, O. A unique exonic splicing mutation in the human androgen receptor gene indicates a physiologic relevance of regular androgen receptor transcript variants. *J. Clin. Endocrinol. Metab.* 86:2569-75, 2001.

10 Hide, W.A., Babenko, V.N., van Heusden, P.A., Seoighe, C. and Kelso, J.F. The contribution of exon-skipping events on chromosome 22 to protein coding diversity. *Genome Res.* 11:1848-53, 2001.

Hubank, M., and Schatz, D.G. Identifying differences in mRNA expression by representational difference analysis of cDNA. *Nucleic Acids Res.* 15 22:5640-5648, 1994.

Keydar, I., Ohno,T., Nayak, R., Sweet, R., Simoni, F., Weiss, F., Karby, S., Mwsa-Tejada, R. and Spiegelman, S. Properties of retrovirus-like particle produced by a human breast cancer cell line: immunological relationship with mouse mammary tumor virus proteins. *Proc. Natl. Acad. Sci. USA* 81:4188-20 4192, 1984.

Kienzle N., Young D.B., Liaskou D., Buck M., Greco S., and Sculley T.B. Intron Retention May Regulate Expression of Epstein-Barr Virus Nuclear Antigen 3 Family Genes. *J Virology* 73:1195-1204, 1999.

Krug, R.M. The regulation of export of mRNA from nucleus to cytoplasm. *Curr. Opin. Cell Biol.* 5:944-949, 1993.

25 Labat, M.L. Possible retroviral etiology of human breast cancer. *Biomed and Pharmacother.* 52:6-12, 1998.

Lisitsyn, N., Lisitsyn, N., and Wigler, M. Cloning the difference between two complex genomes. *Science* 259: 946-951, 1993.

Lisitsyn, N.A., Lisitsina, N.M., Dalbagni, G., Barker, P., Sanchez, C.A., Gnarra, J., Linehan, W.M., Reid, B.J., and Wigler M.H. Comparative genomic analysis of tumors: Detection of DNA losses and amplification. Proc. Natl. Acad. Sci. USA 92: 151-155, 1995.

5 Matsumoto, K., Wassarman K.M. and Wolfe A.P. Nuclear history of a pre-mRNA determines the translational activity of cytoplasmic mRNA. EMBO J. 17:2107-2121, 1998.

Matsumura, Y., Sugiyama, M., Matsumura, S., Hayle, A.J., Robinson, P., Smith, J.C. and Tarin, D. Unusual retention of introns in CD44 gene transcripts

10 in bladder cancer provides new diagnostic and clinical oncological opportunities. J. Path. 177:11-20, 1995.

Moore, D.H., Charney, J., Kramarsky, B., Lasfargues, E.Y. and Sarkar, N.H. Search for a human breast cancer virus. Nature 229:611-615, 1971.

Nakai, K. and Sakamoto, H. Construction of a novel database containing

15 aberrant splicing mutations of mammalian genes. Gene 141:171-177, 1994.

Nishizawa, T., Okamoto, H., Konishi, K., Yoshizawa, H., Miyakawa, Y. and Mayumi, M. A novel DNA virus (TTV) associated with elevated transaminase levels in posttransfusion hepatitis of unknown etiology. Biochem. and Biophys. Commun. 241: 92-97, 1997.

20 Oettgen, P., Carter, K.C., Augustus, M., Barcinski, M., Boltax, J., Kunsch, C. and Libermann, T.A. The novel epithelial-specific Ets transcription factor gene ESX maps to human chromosome 1q32.1. Genomics 45:456-457, 1997a.

Oettgen, P., Alani, R.M., Barcinski, M.A., Brown, L., Akbarali, Y., Boltax, J., Kunsch, C., Munger, K., and Liberman, T.A. Isolation and characterization of

25 a novel epithelium specific transcription factor, ESE-1, a member of the ets family. Mol. Cell. Biol. 17: 4419-4433, 1997b.

Oettgen, P., Barcinski, M., Boltax, J., Stolt, P., Akbarali, Y. and Libermann, T.A. Genomic organization of the human ELF3 (ESE-1/ESX) gene, a member of the Ets transcription factor family, and identification of a

30 functional promotor. Genomics 55: 358-362, 1999.

Piedrafita F. J., Molander R.B., Vasant, G, Orlova E.A., Pfahl M., and Reynolds W.F. An Alu Element in the myeloperoxidase promotor contains a composite SP1-thyroid hormone-retinoic acid response element. *J Biol. Chem.* 271:14412-14420, 1996.

5 Pogo B.G. and Holland J.F. Possibilities of a viral etiology for human breast cancer. A review. *Biol Trace Elem. Res.* 56:131-142, 1997.

Poiesz B.J., Ruscetti F.W., Gadzar A.F., Bunn P.A., Ninna J.D., and Gallo R.C. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patients with cutaneous T-cell lymphoma. *Proc. Natl Acad Sci USA* 77:7415-7419, 1980.

10 Rohlfs E.M., Puget N., Graham M.L., Weber B.L., Garber J.E., Skrzynia C., Halperin J.L., Lenoir G.M., Silverman L.M., and Mazoyer S. An Alu-mediated 7.1 kb deletion of BRCA1 exons 8 and 9 in breast and ovarian cancer families that results in alternative splicing of exon 10. *Genes Chromosomes Cancer* 28(3):300-7, 2000.

15 Rosen P.P. Pages 249-343, Chapters 13, 14, 15 in Rosen's *Breast Pathology* Second Edition Lippincott Williams and Wilkins, Philadelphia, 2001a.

Rosen P.P. Lobular Carcinoma In Situ and Atypical Lobular Hyperplasia. Pages. 581--626, Chapters 33 in Rosen's *Breast Pathology* Second Edition.

20 Lippincott, Williams and Wilkins, Philadelphia, 2001b.

Roux K.H. Optimization and troubleshooting in PCR. *PCR Methods Appl.* 4: 5185-5195, 1995.

Roy-Engel A.M., et al. Alu insertion polymorphisms for the study of human genomic diversity. *Genetics* 159:279-290, 2001.

25 Schmid C.W. Does SINE evolution preclude Alu function? *Nucl. Acid Res.* 26:4541-4550, 2000.

Sigfusson B.F., Anderson I, Aspergren K et al. Clustered breast calcifications. *Acta Radiol* 24:373-381, 1983.

-8-

Stella A., Wagner A., Shito K., Lipkin S.M., Watson P., Guanti G., Lynch H.T., Fodde R. and Liu B. nonsense mutation in MLH1 causes exon skipping in three unrelated HNPCC families. *Cancer Res.* 61:7020-4, 2001.

5 Stutz F. and Rosbash M. Nuclear RNA export. *Genes Devel.* 12:3303-3319, 1998.

Szmulewicz M.N., Novick G.E., and Herrera R. J. Effects of Alu insertions on gene function. *Electrophoresis* 19:1260-1264, 1998.

Tabar L, Akerlund E, Gad A. Five-year experience with single-view mammography randomized controlled screening in Sweden. *Recent Results 10 Cancer Res.* 90:105-113, 1984.

Tymms M.J., Ng A.Y.N., Thomas, R.S., Schutte, B.C., Zhou, J., Eyre, H.J., Sutherland, G.R., Seth, A., Rosenberg, M., Papas, T., Debouck, C., and Kola, I. A novel epithelial-expressed ETS gene, ELF3: human and murine cDNA sequences, murine genomic organization, human mapping to 1q32.2 and 15 expression in tissues and cancer. *Oncogene* 15: 2449-2462, 1997.

Vansan G., and Reynolds W.F. The consensus sequence of a major Alu subfamily contains a functional retinoic acid response element. *Proc Natl Acad Sci USA* 92:8229-8233, 1995.

20 Verbeek ALM, Hendriks JHCL, Holland R. et al. Reduction of breast cancer mortality through mass screening with modern mammography: first results of the Nijmegen Project. 1975-81. *Lancet* 1:1222-1224, 1984.

Wang Y., Holland J.F., Bleiweiss I.J., Melana S., Liu X., Pelisson I., Cantarella A., Stellrecht K., Manis S. and Pogo B.G. Detection of mammary tumor virus env gene-like sequence in human breast cancer. *Cancer Res.* 25 55:5173-5179, 1995.

Wang Y., Go V., Holland J.F., Melana S.M. and Pogo B.G. Expression of mouse mammary tumor virus-like env gene sequences in human breast cancer. *Clin Cancer Res* 4:2565-256. 1998.

-9-

Wellings SR, Jensen HM, Marcum RG. An atlas of subgross pathology of the human breast with special reference to possible precancerous lesions. J. Natl Cancer Inst. 55:231-275, 1975.

Yoshida, K., Bolodeoku, J., Sugino, T., Goodison, S., Matsumura, Y.,
5 Warren B.F., Toge, T., Tahara, E. and Tarin, D. Abnormal retention of intron 9 in CD44 gene transcripts in human gastrointestinal tumors. Cancer Res. 55:4273-4277, 1995.

Yuan, L., Shan, J., De Risi, D., Broome, J., Lovecchio, J., Gal, D., Vinciguerra, V., and Xu, H.P. Isolation of a novel gene, TSP50, by a
10 hypomethylated DNA fragment in human breast cancer. Cancer Res. 59 :3215-3221, 1999.

U.S. Patent No. 6,326,173.

U.S. Patent No. 6,436,909.

The diagnosis of breast cancer requires great skill by pathologists to
15 properly classify biopsies into current pathological groupings. The proper interpretation of pathological findings has great consequences to patients as it can result in varying treatments for primary cancer. However, there remains confusion about the relationship between different forms of breast cancer. For example, there is uncertainty as to how invasive lobular cancer is different from
20 invasive duct carcinoma. It is also not known whether all forms of invasive duct carcinoma are the same.

In spite of burgeoning molecular genetic technology and widespread human genome sequence information, no unique genetic marker has been found for the most common forms of breast cancer. The BRCA I and II genes have
25 been useful in identifying patients at risk for familial forms of breast and ovarian cancer, but only a small percentage of most breast cancers occur in patients with the BRCA abnormalities. BRCA genes can be tested from DNA isolated from peripheral blood but this technology is not offered routinely to most women with breast cancer. Gene chip technology allows scientists to look

-10-

for overexpression or underexpression of otherwise normal genes. Studies with gene chips are beginning to reveal various patterns of gene expression in breast cancer cells that do not occur with normal cells. However, gene chip technology is complex and expensive and is currently performed on actual

5 biopsy tissue, which is not always available.

Another genetic marker, the ELF3 gene, is overly expressed in intraductal carcinoma (also called ductal carcinoma in situ [DCIS]). The ELF3 protein belongs to the ETS family of transcription factors, which contain a helix-loop-helix motif that is required to bind in the major groove of DNA sequences

10 centered over a conserved core GGAA/T motif, and which is important for HER2/neu function (Chang et al., 1997; Oettgen et al., 1997a; Tymms et al., 1997; Andreoli et al., 1997; Choi et al., 1998; Chang et al., 1999; Oettgen et al., 1999; Oettgen et al., 1997b).

The ELF3 gene, which has also been called ESE-1, ERT, jen, and ESX, is a

15 member of the subfamily of ELF (E74-like-factor) genes. The human ELF3 gene contains 9 exons and 8 introns (Chang et al., 1999; Oettgen et al., 1999), is located on chromosome 1q32.1-32.2 (Oettgen et al., 1997a; Tymms et al., 1997), and its transcribed RNA product is ~5.8 kb. It is thought to be expressed only in epithelial cells (Chang et al., 1997; Tymms et al., 1997;

20 Brembeck et al., 2000) and its expression is induced during epidermal differentiation. The epithelial-specific expression pattern of ELF3 is unique among members of the Ets family, and to date very few epithelial-specific transcription factors have been identified. Its DNA-binding domain, conserved among all Ets family members, is located in exons 8 and 9 (Oettgen et al.,

25 1999).

As a transcriptional regulatory gene, ELF3 overexpression or alteration may play a role in carcinogenesis. ELF3 mRNA is overexpressed in ductal carcinoma in situ (DCIS) (Id.) in which there is a high incidence of HER2/neu amplification and overexpression (Barnes et al., 1992). Excess chromosome 1 is

-11-

common in breast cancer (as well as lung and prostate cancer), and ELF3 may be similarly amplified.

Currently, it is believed that DCIS is the precursor lesion of invasive duct carcinoma (Rosen, 2001a). DCIS apparently arises from the terminal 5 duct-lobular unit where the cell of origin is believed to be a terminal ductal epithelial cell (Rosen, 2001a, Wellings, 1975). Many different forms of DCIS exist including comedo, cribriform, micropapillary and solid type (Rosen, 2001a). Diagnoses of these forms of DCIS have been increasing in part because mammography has played an increasingly major role in detecting these often 10 non-palpable tumors. As many as 43% of tumors detected mammographically have been DCIS (Andersson, 1984; Sigfusson et al., 1983; Tabar et al., 1984; Verbeek et al., 1984; Fonseca et al., 1997). Invasive duct carcinoma is believed to occur when the ductal carcinoma cells breach the myoepithelial basement membrane and invade into the stroma. Invasive duct carcinoma is often found 15 in conjunction with a DCIS lesion (Rosen, 2001a).

DCIS is generally distinctly different from lobular carcinoma which can also form both *in situ*-like lesions (lobular carcinoma *in situ*) and invasive lesions (invasive lobular carcinoma). Lobular carcinoma *in situ* arises from the lobular cell itself (Rosen, 2001b). Most authorities do not consider lobular 20 carcinoma *in situ* as a neoplastic lesion but as an indicator of increased cellular activity. This increased cellular activity is associated with an increased risk of other forms of breast cancer notably DCIS and invasive duct carcinoma as well as invasive lobular carcinoma. Some authorities feel, however, that lobular carcinoma *in situ* is the precursor lesion of invasive lobular carcinoma. Lobular 25 carcinoma *in situ* lesions are inconspicuous and non-palpable, are often multicentric, can form signet ring-like cells and are associated with a distinctive type of infiltration (Rosen, 2001a). Mucin can be seen in an intracytoplasmic location in these cells. C-adherins are absent from these lesions. The cellular origin of these lesions is presumed to be the lobular cell.

Currently there is no genetic marker present that distinguishes lesions of terminal duct origin from those of lobular origin. In biopsy material from neoplastic breasts lesions, these different cancers can be distinguished using some stains of mucin, cytokeratin and C-adherin, but there is no useful genetic marker that distinguishes these different cancers.

There is thus a need for new genetic markers to identify breast cancer, particularly DCIS. The present invention provides such markers.

Summary of the Invention

Accordingly, the present invention is based on the discovery of an
10 association between cancer and novel ELF3 gene and/or ELF3 message (mRNA)
sequences. The novel sequences include intron retention in the mRNA, a novel
Alu sequence in the ELF3 gene and a novel 5' untranslated region (UTR) in the
ELF3 gene.

Thus, in some embodiments, the present invention is directed to cDNAs of a human ELF3 gene. In these embodiments, the cDNAs comprise an intron of the ELF3 gene or a portion of an intron of the ELF3 gene. Vectors comprising the cDNA and cells transfected with those vectors are also envisioned.

In other embodiments, the invention is directed to sets of two primers useful for amplifying any of the ELF3 sequences associated herein with cancer, e.g., mRNA retaining an ELF3 intron, Alu_{kwd}, and the novel 5' UTR described herein.

The present invention is additionally directed to isolated nucleic acids or mimetics comprising a sequence homologous to at least a portion of an intron of a human ELF3 gene.

25 The invention is also directed to isolated nucleic acids or mimetics comprising a sequence at least 95% homologous to SEQ ID NO:13 or SEQ ID NO:15.

Vectors comprising any of the above nucleic acids or mimetics, and cells comprising those vectors, are also within the scope of the invention.

-13-

Additionally, the invention is directed to probes comprising any of the above nucleic acids or mimetics. In these embodiments, the probes further comprise a detectable label.

In additional embodiments, the invention is directed to pairs of cell cultures, where each cell culture is of the same tissue type and is derived from cancerous mammalian tissue, and where one of the cell lines is of cancerous cells and the other cell line is of matched noncancerous cells.

The present invention is also directed to methods for determining whether a patient has cancer or is at risk for cancer. The methods comprise evaluating whether a cell in the patient comprises an ELF3 nucleic acid sequence disclosed herein to be associated with cancer. These sequences include an ELF3 mRNA retaining at least a portion of an intron, SEQ ID NO: 15, and an Alu_{kwd} .

The invention is additionally directed to kits for evaluating whether a patient has cancer or is at risk for cancer. These kits comprise sets of two primers homologous to a portion of an ELF3 gene. The primers are useful for determining whether the patient comprises a nucleic acid sequence described herein as associated with cancer. These sequences include ELF3 mRNA retaining at least a portion of an intron, the novel ELF3 gene 5' UTR, and Alu_{kwd} . The kits also comprise instructions directing the use of the primers for determining whether a nucleic acid sequence amplified by the primers is present in a nucleic acid preparation.

In related embodiments, the invention is directed to additional kits for evaluating whether a patient has cancer or is at risk for cancer. These kits comprise probes useful for determining whether the patient comprises a nucleic acid sequence described herein as associated with cancer. These sequences include ELF3 mRNA retaining at least a portion of an intron, the novel ELF3 gene 5' UTR, and Alu_{kwd} . The kits also comprise instructions directing the use of the probe for determining whether a nucleic acid sequence homologous to the probe is present in a nucleic acid preparation.

In additional embodiments, the invention is directed to methods for determining whether a cell or other sample comprises a virus. The methods comprise adding contents of the cell or adding a portion of the sample to a culture, where the culture comprises a susceptible cell that is capable of

5 acquiring a particular characteristic upon infection with a virus. The particular characteristic can be intron retention of ELF-3 mRNA and/or acquisition of [Alu_{kwd}] in an ELF3 gene. The methods further comprise determining whether the susceptible cell has acquired the characteristic after addition of the contents of the cell.

10 **Brief Description of the Drawings**

FIG. 1 shows results from experiments relating to genomic DNA Southern blots for probe GC3. Panel A shows a Southern blot using probe GC3 with 5 µg of *Hpa*II and *Msp*I digested genomic DNA prepared from K151 breast cancer cell cultures (lane T) and normal cell lines from the same effusion (lane N). The

15 GC3 probe only hybridized to tumor genomic DNA, but not to normal amplicon DNA with either *Hpa*II or *Msp*I digestion. Panel B shows the *Hpa* II or *Msp* I digested tumor (lane T) and normal (lane N) genomic DNA electrophoresis before transfer to the blot membrane for GC3 probe treatment, which served as the DNA digestive and quantitative control.

20 FIG. 2 shows a gel of electrophoresed PCR products establishing the presence of the GC3 202 bp DNA fragment in both breast tumor and normal cell lines. DNA isolations from 3 breast tumor cell lines and matched normal cell lines were amplified by GC3 primers, designed from the GC3 DNA sequence, in PCR reactions. Lane M, 100bp DNA ladder; lane T and N represent tumor and

25 normal cell lines respectively, GC3 plasmid served as a positive control.

FIG. 3 shows a gel of electrophoresed products from a reverse transcriptase-polymerase chain reaction (RT-PCR) amplification of GC3 in breast tumor cell cultures and matched normal cell cultures. The 202 bp GC3 was amplified from breast tumor cell lines but not matched normal cell lines,

indicating the presence of GC3 in mRNA from the tumor lines but not the normal lines. Lane T, breast tumor cell lines; lane N, normal matching line. K151 is a myofibroblast cell line; K234 is a CD4+ T lymphocyte line. IL-1 served as a positive control for RT-PCR (lane p); lane n, negative control; lane 5 M, 100 bp DNA ladder.

FIG. 4 shows gels of electrophoresed PCR products of cDNAs from breast tumor tissues and matched normal tissues. The gels demonstrate that the 202 bp GC3 fragment is present in mRNA of breast tumor tissues but not in matched normal tissues. Six paired cDNAs from breast tumor and matched normal tissues were amplified by GC3 primers in PCR reactions. GC3 was expressed in four of six breast tumor tissues, but none of the six matched normal tissues (Panel A). The presence of intact input RNA was checked in all samples by amplification of human β -actin (Panel B). Lane M, 100 bp DNA ladder; lane N and T represent normal tissue and breast tumor respectively. The patient ID numbers are below the N and T lanes. DNA from K151 tumor cells were used as a positive control (lane p); double distilled H_2O was used as a negative control in the PCR reactions.

FIG. 5 shows gels of electrophoresed PCR products showing that the 202 bp GC3 product was abolished by RNase digestion of isolated mRNA, but not by DNase I digestion. Total cellular RNA prepared from K151 tumor cell lines was subjected to Dnase I (lane D) and RNase (lane R) digestion before cDNA synthesis. RT-PCR was performed using GC3 primers. The 202 bp GC3 product was produced on the DNase I-digested RNA isolate but not on RNase-digested RNA isolate. The result verified that the 202 bp GC3 is generated by amplification of mRNA; contamination with genomic DNA is excluded.

FIG. 6 shows a gel of electrophoresed PCR products evaluating nuclear or cytoplasmic presence of GC3 in RNA from breast tumor cells. RNA was isolated from nuclear (Nuc) and cytoplasmic (Cyto) fractions. PCR using GC3 primers was performed on the RNA isolates with (RT+) or without (RT-) a prior reverse transcription step. The presence of intact input RNA was checked in all samples

-16-

by amplification of human β -actin. Lane M, 100 bp DNA ladder. DNA from K151 tumor cells was used as a positive control (Pos); ddH₂O was used as a negative control. The GC3 202 bp product was produced from both nuclear and cytoplasmic mRNA from K151 tumor cell lines and nuclear mRNA from MCF7

5 cell lines; weakly produced on cytoplasmic mRNA from MCF7 cell lines; and produced in nuclear mRNA from U937 cell lines only when the mRNA was reverse transcribed to cDNA. No GC3 or β -actin products were produced on RNA isolates without reverse transcription, ruling out contamination of RNA isolates with genomic DNA.

10 FIG. 7 shows a gel of electrophoresed PCR products evaluating GC3 expression on cDNA libraries from K151 tumor cell lines for 5' RACE and RT-PCR. The 5' RACE cDNA library was synthesized by modified lock-docking oligo(dT) primer and SMART II oligo (SMART RACE cDNA Amplification Kit, Clontech Inc.); cDNA was synthesized by oligo (dT)16 (RNA PCR Kit, Perkin

15 Elmer) as well as total cellular RNA, and was amplified using GC3 primers. GC3 was amplified from both tumor cell lines, regardless of the method employed for cDNA synthesis. More importantly, GC3 was not amplified from 1 μ g total cellular RNA from K151 tumor cell lines and 3 μ g total cellular RNA from K259 tumor cell lines, demonstrating no genomic DNA contamination in

20 the RNA isolations. A GC3 plasmid was used as a positive control for the PCR reaction.

FIG. 8 shows a gel of electrophoresed PCR products evaluating 5' RACE and 3' RACE results from K151 and K259 cDNA. cDNAs for 5' RACE and 3' RACE were synthesized by using RNA from K151 and K259 breast tumor cell lines. In the 5' RACE, GC3 UPF (SEQ ID NO:18) and GC3 UPN (SEQ ID NO:19) were used as the first and second primers. In 3' RACE, GC3 DF (SEQ ID NO:20) and GC3 DN (SEQ ID NO:21) were used as the first and second primers.

FIG. 9 shows schematic diagrams illustrating different forms of the ELF3 gene and their relation to cancer. Panel a shows the genomic organization of

30 the human ELF3 gene. Exons 1 to 9 are represented by filled boxes, and the

-17-

introns in between are represented by lines. Panel b shows where unspliced ELF3 mRNA was found. The entire intron 4, 5 and 6, as determined by 5' RACE, and the GC3 fragment, as determined by RT-PCR, are indicated. The numbers indicate the locations in the genomic sequence. Panel c shows the 5 fully spliced ELF3 mRNA. The exon 1 in the darkened box indicates a different 5' UTR from previously published sequences.

FIG. 10 shows a gel of electrophoresed PCR products evaluating the presence of spliced ELF3 mRNA in breast tumor cell lines in RT-PCR reactions. Primers 1-3, 3-6, 6-8 and 8-9 amplified ELF3 exon 1 to 3, 3 to 6, 6 to 8 and 8 to 10 9 respectively. The length of DNA fragments with and without intron retention are labeled. DNA fragments without intron retention were observed in exon 1 to 3, 3 to 6, 6 to 8 and 8 to 9 on both breast tumor cell lines K151 and K259.

FIG. 11 shows gels of electrophoresed PCR products evaluating GC3 presence in genomic walking steps. Panel A. Up-stream walking; Panel B. 15 Down-stream walking; Panel C. Down-down stream walking. Lane M: 100bp DNA ladder. Lane 1. *Dra*I library; Lane 2. *Stu*I library; Lane 3: *Pvu*II library; Lane 4: *Eco*RV library.

FIG. 12 shows a gel of electrophoresed PCR products evaluating the presence of the 315bp *Alu*_{kwd} sequence exemplified herein, in normal and breast 20 cancer patients. The DNA from breast cancer cell lines (K151T, K234T and K259T), normal cell lines from patient with breast tumor (K234 N) and normal cells from donors without breast cancer (donor J and donor S) were amplified with *Alu*_{kwd} primers. The 451bp DNA fragment was amplified in all samples. A plasmid containing the *Alu*_{kwd} DNA fragment from K151 tumor cells was used as 25 a positive control.

FIG. 13 shows gels of electrophoresed PCR products establishing *Alu*_{kwd} retention in mRNA of breast tumor cell lines, but not normal cells. cDNA from K151 and K234 breast tumor and matched normal cell lines (lanes K151 and K234 T and N, respectively); K259 breast tumor cell line and donor 1 PBMC 30 (lane K259-T and N, respectively); and MCF-7 breast cancer cell line were

-18-

amplified by Alu primers (A) and β -actin primers (B). Alu_{kwd} was present in mRNA from all breast tumor cells and no normal cells. β -actin presence in similar amounts in all samples except the negative control indicated RNA integrity and equivalent quantity in all of the samples tested.

5 FIG. 14 shows gels of electrophoresed PCR products evaluating ELF3 intron 7 retention in mRNA in peripheral blood mononuclear cells (PBMC) from breast cancer patients with clinical remission. The mononuclear cells from pleural effusion (PE cells) in the late stage of breast cancer patients and PBMC in the remission period of breast cancer patients were used for RNA isolation.

10 10 Synthesized cDNA was amplified with GC3 primers for intron 7 retention (Panel A) and β -actin primers for RNA integrity and quality control (Panel B). Intron 7 retention occurred in 2 of 3 cell preparations from pleural effusion of late stage of breast cancer patients and in 1 of 3 PBMC from early stage of breast cancer with clinical remission.

15 15 FIG. 15 shows gels of electrophoresed PCR products establishing the association of ELF3 mRNA multiple intron retention in PBMC with the human breast cancer DCIS. cDNA from 10 breast cancer patients were amplified with GC3 primers to test for intron 7 retention (Panel A), Alu_{kwd} primers to test for intron 8 retention (Panel B), and β -actin primers for RNA quality control (Panel C). The results showed intron 7 retention occurred in 4 of 5 PBMC from patients with breast cancer with DCIS subtype and 0 of 5 PBMC from patients with breast cancer with other subtypes. Intron 8 Alu_{kwd} retention occurred in PBMC from 3 of 5 patients with breast cancer with DCIS subtype and 0 of 5 patients with other subtypes of breast cancer. K151 5' RACE cDNA library served as a positive control in all assays.

20 FIG. 16 shows gels of electrophoresed PCR products establishing that Alu_{kwd} is present in retained intron 8 in ELF3 mRNA of breast tumor tissues but not matched normal tissues. cDNA from 8 sets of breast tumor and matched normal tissues were amplified by Alu_{kwd} primers. Alu_{kwd} was present in ELF3 mRNA of 5 of 8 breast tumor tissues and 0 of 8 normal tissues (Panel B).

-19-

Integrity and quantity of RNA was checked in all samples by amplification of human β -actin (Panel A). Lane M, 100 bp DNA ladder; lane N and T represent normal tissue and breast tumor respectively. The patient ID numbers are below the N and T lanes. DNA from K151 tumor cells was used for a positive control 5 (lane p); ddH₂O was the negative control (lane n).

FIG. 17 shows gels of electrophoresed PCR products establishing the presence of Alu_{kwd} expression in cytoplasmic and nuclear RNA in human breast cancer cell lines. Nuclear and cytoplasmic RNA was purified from human breast cancer cell lines K151, K259 and MCF-7, human cervical carcinoma cell lines 10 C33-A, human histiocytotic lymphoma cell lines U-937, and human acute T cell leukemia cell line Jurkat. Integrity and quantity of RNA was checked in all samples by amplification of human β -actin (Panel A). Alu_{kwd} was present in cytoplasmic and nuclear RNA from human breast cancer cell lines K151, K259 and MCF-7, and in C33-A and U-937 nuclear but not cytoplasmic RNA, and was 15 absent in Jurkat cytoplasmic and nuclear RNA (Panel B). Negative Alu_{kwd} PCR results in the same RNA isolation run in the same test demonstrated there were no DNA contamination in these RNA isolation (Panel C).

FIG. 18 shows gels of electrophoresed PCR products demonstrating that the Alu_{kwd} and β -actin product was abolished by RNase digestion of RNA but not 20 by DNase I digestion. Total cellular RNA prepared from the K151 tumor cell line was subjected to DNase I (lane D) and RNase (lane R) digestion prior to cDNA synthesis. RT-PCR was performed using β -actin primers (Panel A) and Alu_{kwd} primers (Panel B). The expected PCR product was produced from the DNase I-digested RNA isolate but not from the RNase-digested RNA isolate, 25 when both the β -actin and Alu_{kwd} primers were used. The result verifies that the 415 bp Alu_{kwd} product is generated by amplification of mRNA; contamination with genomic DNA is excluded. An RNA isolation from the K151 tumor cell line without digestion was used as positive control for RT-PCR (pos 1); DNA from the K151 tumor cell was used as a positive control for the PCR reaction (pos 2); 30 ddH₂O was used as a negative control in the RT-PCR reaction (neg).

FIG. 19 shows gels of electrophoresed PCR products demonstrating ELF3 mRNA retention of intron 7 in breast tumor cells. Various concentrations of intron 7-expressing cells (K259 tumor cell lines) were spiked into 2×10^6 PBMC prepared from a normal blood donor. cDNA from those samples were amplified 5 with GC3 primers for intron 7 expression (Panel A) or β -actin primers for RNA integrity and quality control (Panel B). In the same experiment, the RNA isolates were also amplified with β -actin primers to detect DNA contamination in those RNA isolates (Panel C). Negative (neg) and positive (pos) controls were ddH₂O and RNA from the K151 tumor cell line, respectively. Intron 7 10 retention was observed at a K259 breast tumor cell concentration from 10^6 to 10^3 per 2×10^6 normal cells. Positive β -actin expression in all samples that were reverse transcribed demonstrated equal amount of RNA input in RT-PCR reaction; negative β -actin expression in the RNA isolates that were not reverse transcribed ruled out the possibility of DNA contamination.

15 **Detailed Description of the Invention**

The present invention is based on the discovery of novel ELF3 gene and ELF3 message (mRNA) sequences. The novel sequences include intron retention in the mRNA; a novel Alu sequence in the ELF3 gene and mRNA; and a novel 5' untranslated region (UTR) in the ELF3 gene. These novel sequences, 20 which can be isolated from cancerous tissue biopsies as well as peripheral blood mononuclear cells (PBMCs), are associated with the presence of cancer in a patient having the novel sequences. In particular, the sequences are associated with breast cancer, especially ductal carcinoma in situ (DCIS).

Based on the association between the sequences and cancer, methods 25 which detect the presence of any of the sequences in a patient is useful in the diagnosis of cancer.

While the strongest association of the presence of these sequences is with DCIS, the sequences have also been associated with other cancers, in particular other forms of breast cancer, and methods for detecting other forms of cancer

-21-

using these sequences are also useful. Nevertheless, the very strong association with DCIS allows one to distinguish DCIS from other forms of breast cancer using these sequences with a high probability.

Thus, in some embodiments, the invention is directed to cDNAs of a

5 mammalian ELF3 gene, or fragments thereof at least 20 nucleotides long, which comprise an intron of the ELF3 gene or a portion of an intron of the ELF3 gene. Fragments of the cDNA are preferably longer than 20 nucleotides long, for example at least 50, at least 100, at least 500, or at least 1000 nucleotides long.

10 As used herein, a cDNA has its common meaning, that is a DNA comprising the sequence of a reverse-transcribed polyA-containing mRNA. This includes amplified products of the reverse-transcribed mRNA, such as products from an RT-PCR procedure. Since a cDNA is a reflection of the mRNA that is present, an ELF3 cDNA that retains an intron of the ELF3 gene indicates that the

15 mRNA has inappropriately retained an ELF3 gene intron, which is associated with cancer, particularly DCIS (See Example 1). An example of a normally spliced ELF3 cDNA (without an intron or portion) is provided as SEQ ID NO:2.

In preferred embodiments, the ELF3 cDNA comprises intron 4, intron 5, intron 6, intron 7, intron 8, portions of any of those introns, or combinations of

20 any of those introns or portions. Introns 4, 5, 6, 7 and 8 of the ELF3 gene can be readily identified by the skilled artisan by consulting public databases such as GenBank, where a human ELF3 gene is provided as Accession AF110184 (SEQ ID NO:1). An amino acid sequence (SEQ ID NO:3), the translation of SEQ ID NO:1 (after mRNA processing), is also provided under Accession AF110184.

25 See Appendix, identifying SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8 and SEQ ID NO:9 as introns 4, 5, 6, 7 and 8, respectively.

An example of a retained sequence that is associated with cancer is SEQ ID NO:11 (Example 1 - also identified therein as GC3), which is present in the mRNA (and derived cDNA) of cancer patients as retained portions of introns 7

30 and 8.

These embodiments are not limited to any specific ELF3 cDNA or intron sequences such as SEQ ID NO:2, 5, 6, 7, 8, or 9. Rather, homologous sequences from any mammal, or alternative human sequences are also envisioned as within the scope of the invention. The skilled artisan would understand that

5 there could be small variations among ELF3 gene, cDNA, or amino acid sequences between mammals, or among humans. For example, SEQ ID NO:3 and SEQ ID NO:4 provide alternative amino acid sequences resulting from the translated gene provided as SEQ ID NO:1 (starting at nt 5319) and the cDNA SEQ ID NO:2, respectively (see Appendix).

10 In some aspects of these embodiments, the cDNA or portion also comprises an Alu_{kwd} . Alu_{kwd} is a novel Alu sequence that is present inserted into ELF3 introns in cancerous tissue as well as PBMCs of cancer patients (see Example 2). In particular, Alu_{kwd} is found in breast cancer, especially DCIS.

One example of Alu_{kwd} consists of the sequence provided herein as SEQ 15 ID NO:13. However, based on the understanding that Alu sequences have many variants, such that they can be logically divided into families that are at least about 90%, more preferably 95%, homologous to each other (Roy-Engel et al., 2001), it would be expected that Alu_{kwd} exists as several different sequences that are at least about 90% homologous to each other. It would also be 20 expected that any one of those forms of Alu_{kwd} would be associated with cancer.

In preferred embodiments, the Alu_{kwd} is found in cDNAs of cancer patients within a retained intron 8. In more preferred embodiments, the Alu_{kwd} is between nucleotides 8762 and 8763 using the numbering of SEQ ID NO:1.

25 In some embodiments, the cDNA of the present invention comprises the entire ELF3 gene coding region, i.e., from the 5' UTR to the polyA tail. In other embodiments, the cDNA consists of only a fragment of the full length coding region, comprising at least 20 nucleotides of the coding region. The latter fragment could be obtained through reverse transcription polymerase chain reaction (RT-PCR) of cellular mRNA or total RNA, using PCR primers that do 30 not amplify the entire coding region. Such methods are well known.

In some preferred embodiments, the cDNA comprises introns 4, 5, 6 and 7 of the ELF3 gene, for example those provided as SEQ ID NO:5, 6, 7 and 8, respectively. In other embodiments, the cDNA comprises the 5' UTR of the ELF3 mRNA. Preferably, the 5' UTR comprises the nucleotide sequence

5 provided herein as SEQ ID NO:15, or a variant of SEQ ID NO:15 that is at least about 90% homologous to SEQ ID NO:15..

A preferred example of a full length cDNA comprising SEQ ID NO:15 is SEQ ID NO:2, where the cDNA is interspersed by one or more introns.

In preferred embodiments, the cDNA of the present invention is prepared

10 from a composition comprising a cell, for example a tissue sample from a patient or from PBMCs. In some of these embodiments, the cell further comprises genomic DNA comprising an Alu_{kwd}, for example consisting of SEQ ID NO:13. Preferably, the Alu_{kwd} is between nucleotides 8762 and 8763 of an ELF3 gene in the cell, using the numbering of SEQ ID NO:1.

15 In other preferred embodiments, the cDNA is prepared from a composition comprising a cell, where the cell obtained from a patient being tested for breast cancer. Preferably, the patient is at high risk for breast cancer. In these embodiments, the cell composition is preferably a PBMC composition or a biopsy of tissue (preferably breast tissue) or an effusion suspected of being

20 cancerous.

The preparation of the cDNA can be using any method known in the art. In preferred embodiments, the cDNA is prepared using RT-PCR. Those RT-PCR methods would utilize primers suitable for amplifying at least a portion of an ELF3 gene sequence suspected of being associated with cancer, such as ELF3

25 intron 4, 5, 6, 7 or 8, an Alu_{kwd}, or the novel ELF3 5' UTR identified herein. See Examples.

Included herein as an RT-PCR technique is the nucleic acid sequence-based amplification ("NASBA") method, as described, for example, in U.S. Patent No. 6,326,173, and references cited therein.

Primers (i.e., a set of two primers) are suitable for amplifying a region of an ELF3 gene when the primers flank the region and allow amplification of that region using PCR. Sequence-specific primers related to a mammalian ELF3 gene, ELF3 mRNA or corresponding cDNA, or to an intron of the ELF3 gene are 5 also useful in methods of detecting target ELF3 sequences by sequencing reactions, as an alternative to PCR-based methods.

The present invention is also directed to vectors comprising any of the above-described cDNAs. As used herein, a vector takes its common molecular biology meaning, that is a piece of nucleic acid capable of replication in a host 10 cell. Preferred examples include plasmid vectors and viral vectors. Such vectors are useful for preserving and increasing the amount of a cDNA in a cell.

In related embodiments, the invention is also directed to cells transfected with any of the above vectors, such that the vector is capable of replication in the cell. Any cell supporting replication of the vector, including prokaryotic and 15 eukaryotic cells, is envisioned as within the scope of these embodiments. Also included are cells where the vector sequence comprising the cDNA is integrated into a chromosome of the cell, or where the vector autonomously replicates in the cell, independent of chromosomal replication.

In other embodiments, the invention is directed to various isolated 20 nucleic acid or mimetic sequences. Each of the sequences is useful for, e.g., determining whether the sequence is present in a sample, for example a PBMC preparation or a biopsy. The sequences are preferably greater than 10 or 20 nucleotides long and less than 50 kB. More preferably, the sequences are less than 12 kB. An example of a useful sequence less than 12 kB is a full length 25 sequence of the ELF3 gene from a patient being diagnosed for cancer, e.g., DCIS. The sequence could be analyzed for the novel 5' UTR or the novel Alu_{kwd} both identified in the experiments discussed in the Examples. In other aspects the sequences are less than 2 kB, or 1 kB, or 500 nt, e.g., to be able to more usefully clone the novel 5' UTR or the novel Alu_{kwd}, perhaps with flanking 30 sequences, into a vector to clone into a cell such as an *E. coli* or a mammalian

-25-

cell/ Optionally, the sequences can incorporate a detectable label, to identify the novel 5' UTR, the novel Alu_{kwd}, or any intron retained in an ELF3 sequence by hybridization.

These sequences can be comprised of DNA, RNA or a mimetic. As used
 5 herein, a mimetic is a nucleotide analog that differs chemically from a naturally occurring nucleotide, but that is capable of oligonucleotide-like noncovalent binding to a homologous nucleotide sequence. See, e.g., U.S. Patent 6,436,909 for a discussion of useful mimetics. A preferred example of a useful mimetic is a phosphorothioate mimetic, which are well known.

10 In some embodiments the nucleic acids or mimetics comprise a sequence homologous to at least a portion of an intron of a human ELF3 gene, and may optionally incorporate a detectable label. These sequences are useful; e.g., for determining if ELF3 mRNA from the sample has retained at least a portion of an intron. In preferred embodiments, the intron to which the nucleic acids or
 15 mimetics are homologous is intron 4, intron 5, intron 6, intron 7 or intron 8, exemplified herein as SEQ ID NO:5, 6, 7, 8 or 9, respectively.

In other embodiments, the nucleic acids or mimetics comprise a sequence at least 95% homologous to at least a portion of SEQ ID NO:13, useful, e.g., for determining whether a member of the Alu_{kwd} family is present in either DNA or
 20 mRNA from the sample. Preferably, the sequence is completely homologous to SEQ ID NO:13. As with previous embodiments, these sequences can optionally comprise a detectable label. The sequence can also comprise regions of the ELF3 gene where the Alu_{kwd} is expected, for example the regions on either side of nucleotides 8762 and 8763 of the ELF3 gene, regions where Alu_{kwd} inserts
 25 (see Example 2).

As used herein, a first sequence is at least 95% homologous to a second sequence when the first sequence is 95% identical to the second sequence or the complement of the second sequence. Where no percentage of homology is used, "homologous" means completely homologous. A sequence, e.g., a primer,

is homologous to a longer sequence, e.g., an ELF3 gene, when the sequence has complete identity to a portion of the longer sequence, or its complement.

In still other embodiments, the nucleotide or mimetic sequence is at least homologous to at least a portion of SEQ ID NO:15, indicating that the

5 novel 5' UTR is present in either DNA or mRNA from the sample. Also useful are sequences encoding an ELF3 open reading frame such as SEQ ID NO:3 or SEQ ID NO:4 or their complement, adjoining the 3' end of SEQ ID NO:15.

Also included within the scope of the invention, are vectors comprising any of the nucleic acids described above. Cells transfected with these vectors

10 are also envisioned. These include either prokaryotic and eukaryotic cells, including cells within multicellular organisms that have been transfected with the vectors to determine the effect of the presence of the nucleic acid on the organism.

In related embodiments, the invention is directed to probes which

15 comprise any of the nucleic acid or mimetic sequences described above, further comprising a detectable label. The labels are useful, for example, for detecting and monitoring the presence of the nucleic acid sequence in an organism or a sample. Many detectable labels are known; the invention is not narrowly limited to any particular type of label. The type of label can be chosen as most 20 appropriate for the particular use being employed. Examples include radioactive, fluorescent, spin, or hapten labels. The latter are labels that are detected using antibodies that specifically bind to the hapten. A well-known example is digoxigenin.

The sequences described herein as being associated with cancer could

25 also be identified using sets of two primers that are suitable to amplify (e.g., using PCR or RT-PCR) and detect those sequences. Thus, the invention is also directed to sets of two primers, wherein each primer is homologous to a portion of the ELF3 gene. Preferably, the primers are less than about 50 nucleotides in length, more preferably less than about 40 nucleotides in length, and most 30 preferably less than about 30 nucleotides in length.

In some aspects, at least one primer is homologous to a portion of an intron of the ELF3 gene. In these aspects, when the primers are used in a procedure such as RT-PCR, the primers amplify a defined mRNA sequence only if an intron was present in the sequence.

5 In other aspects, primers that are homologous only to exon sequences are useful if each of the two primers are homologous to different exons. In that situation, the product of amplification would be one size if intron retention was not present in the amplification product, and a larger size if an mRNA, or a portion thereof, that does retain an intron is amplified.

10 As used herein, a primer is defined as homologous to another nucleotide sequence if that primer is homologous to either strand of the duplex of that sequence, provided the primer is useful when used with another primer in amplification methods. Introns 4, 5, 6, 7, and especially 8 are preferred as targeted by these primers. To determine if Alu_{kwd} is present between

15 nucleotides 8762 and 8763 of the ELF3 gene; one of the primers would be homologous to a region of an ELF3 gene 5' to nt8762 of the ELF3 gene, and the other of the two primers is homologous to a region of the ELF3 gene 3' to nucleotide 8763 of the ELF3 gene.

Other primer sets envisioned herein include sets suitable for amplifying an Alu_{kwd} . Examples of such primer sets are those where one or both primer is at least 95% homologous to SEQ ID NO:13, including those where one or both primers are completely homologous to a portion of SEQ ID NO:13. In the embodiments where only one primer is homologous to SEQ ID NO:13, the other primer is preferably homologous to a portion of an ELF3 gene, such as an intron of an ELF3 gene, for example intron 8, identified in Example 2 to harbor an Alu_{kwd} .

Additional primer sets envisioned as within the scope of the invention are sets suitable for amplifying an ELF3 5' UTR that is at least 95% homologous to SEQ ID NO:15. Preferably, at least one primer is homologous to SEQ ID

NO:13 and the other primer is homologous to an ELF3 gene, for example the 3' end of the open reading frame of an ELF3 gene.

Since it is expected that cancers in any mammal would be associated with the presence of any of the above ELF3 sequences, e.g., mRNAs retaining 5 introns or portions of the ELF3 gene, the novel 5' UTR, Alu_{kwd}, and the novel 5"UTR, the invention encompasses these sequences from any mammalian species, although in preferred embodiments, the mammal is a human.

Any ELF3 nucleotide sequence, including gene, cDNA, mRNA, primer, and probe sequences, and ELF3 amino acid sequences from any mammal can be 10 readily identified by the skilled artisan as being at least about 80% homologous to the analogous sequences provided herein. More preferably, the variants are at least about 90% homologous; even more preferably about 95% or 99% homologous; and most preferably completely homologous to the sequences provided herein. All human ELF3 gene, cDNA and amino acid sequences would 15 be expected to be at least about 95% homologous to the analogous sequences provided herein. The sequence of any mammalian ELF3 gene, cDNA, or amino acid sequence could be obtained without undue experimentation by well known methods.

Also envisioned as within the scope of the invention are pairs of cell 20 cultures, where both cell cultures are of the same tissue type and are derived from cancerous mammalian tissue, and where one of the cell lines is of cancerous cells and the other cell line is of matched noncancerous cells. Examples include pairs of cell cultures prepared as described in Example 1, for example the pair designated K259.

25 The invention is also directed to methods for determining whether a patient has cancer or is at risk for cancer. The methods comprise evaluating whether a cell in the patient comprises any of the ELF3 nucleic acid sequences established herein to be associated with cancer. The sequences include those indicating intron retention in an ELF3 mRNA, the novel 5' UTR (exemplified as 30 SEQ ID NO: 15) and an Alu_{kwd} (exemplified herein as SEQ ID NO:13). The

methods generally utilize any of the novel primers, probes, or nucleic acid sequences described above. These methods are preferably done with a sample of many cells, for example a PBMC preparation or a tissue biopsy from the patient such as from a breast lesion or lymph node with metastatic cancer or a 5 cancerous effusion. As used herein, a biopsy is the removal of tissue from a patient, including the removal of fluid from effusions, for example breast cancer pleural effusions. The cells in the sample can be of one or more than one cell type.

In some embodiments, these methods utilize primers in a polymerase 10 chain reaction (PCR) to amplify DNA to establish the presence or absence of the tested ELF3 sequence. Reverse transcription of mRNA is also useful in some embodiments to prepare cDNA for PCR, e.g., when determining whether mRNA intron retention is present. See discussion of RT-PCR in the Examples. PCR could also be used without reverse transcriptase, for example when determining 15 whether the novel 5' UTR is present in the genome of the cell.

In other embodiments, these methods utilize one of the probes described above in northern hybridization. As is well known, northern hybridization generally involves isolation of mRNA from the cell, electrophoresis of the mRNA on a gel, blotting of the gel to transfer the mRNA to a membrane, and treating 20 the membrane with a probe, to determine whether a sequence homologous to the probe is present on the gel and thus in the mRNA of the cell.

Other embodiments of these methods utilize one of the above-described probes in Southern hybridization. As is well known, Southern hybridization generally involves isolation of DNA from the cell, electrophoresis of the DNA on 25 a gel, blotting of the gel to transfer the DNA to a membrane, and treating the membrane with a probe, to determine whether a sequence homologous to the probe is present on the gel and thus in the DNA of the cell.

The invention is also directed to kits for evaluating whether a patient has cancer or is at risk for cancer. The kits of these embodiments comprise at least 30 one set of two primers that are homologous to a portion of an ELF3 gene,

-30-

wherein the primers are useful for amplifying a nucleic acid sequence established herein to be associated with cancer. As previously discussed, the nucleic acids established herein to be associated with cancer include intron retention in an ELF3 mRNA, the novel ELF3 5' UTRs identified herein

5 (exemplified by SEQ ID NO:15), and an Alu_{kwd} (exemplified herein by SEQ ID NO:13).

These kits also comprise instructions directing the use of the primers for determining whether the nucleic acid sequence is present in a nucleic acid preparation such as an mRNA, cDNA or genomic preparation, as appropriate.

10 These instructions need not be physically associated with the primers, but could refer to the use of the primers from a source physically separated from the primers, e.g., from a web site or a separately mailed paper.

15 As discussed above in the context of the primers of the invention, when the primers are directed to determining whether there is intron retention in an ELF3 mRNA, at least one primer is homologous to a portion of an intron of the ELF3 gene, or the two primers are homologous to portions of the ELF3 gene that flank an intron of the ELF3 gene.

20 In related embodiments, the invention is also directed to other kits for evaluating whether a patient has cancer or is at risk for cancer. These kits comprise a nucleic acid sequence and/or probe, as discussed above, which is useful for determining whether a sample has one of the ELF3 gene sequences identified herein as being associated with cancer. These kits also comprise instructions directing the use of the nucleic acid sequence or probe for determining whether a nucleic acid sequence homologous to the probe is 25 present in the sample.

30 In some embodiments, these kits comprise a gene chip having numerous probes or nucleic acid sequences, for example probes or sequences for each of the retained ELF3 introns and/or ALU_{kwd}. Probes or sequences diagnostic for other diseases, e.g., a BRCA 1 probe, could also be included. Gene chip technology is well known in the art.

-31-

In further embodiments, the presence in a sample of one of the ELF3 gene sequences identified herein as being associated with cancer is detected by sequencing RNA, cDNA or DNA of the sample, wherein the sequencing may be accomplished by any of the various sequencing methods known in the art.

5 The inventors have also discovered that addition of a virus, e.g., Epstein-Barr Virus (EBV), to a cell in culture, for example a BJAB cell, causes ELF3 mRNA intron retention and/or ELF3 Alu_{kwd} appearance. See Example 3. Based on this finding, a cell suspected of harboring a virus that causes ELF3 mRNA intron retention can be easily assayed for presence of a virus.

10 Thus, the invention is also directed to methods for determining whether a cell comprises a virus. The methods comprise a first step of adding the contents of the cell to a culture, where the culture comprises a susceptible cell that is capable of acquiring a characteristic upon infection with a virus. As disclosed herein, the characteristic is ELF3 mRNA intron retention and/or 15 acquisition of an Alu_{kwd}, for example SEQ ID NO:13, in an ELF3 gene. The methods further comprise a second step of determining whether a susceptible cell has acquired either or both of the above characteristics after addition of the contents of the cell. An example of a susceptible cell is a BJAB cell, which is an EBV-negative Burkitt's lymphoma. In preferred embodiments, the virus is 20 related to Epstein-Barr virus, preferably a member of the Herpesviridae, more preferably a member of the Gammaherpesviridae, and most preferably a Lymphocryptovirus.

Preferred embodiments of the invention are described in the following examples. Other embodiments within the scope of the claims herein will be 25 apparent to one skilled in the art from consideration of the specification or practice of the invention as disclosed herein. It is intended that the specification, together with the examples, be considered exemplary only, with the scope and spirit of the invention being indicated by the claims which follow the examples.

Example 1. Unspliced Elf3 Cytoplasmic mRNA in Human Breast Cancer Cells**Example Summary**

Using modified representational difference analysis (mRDA), a DNA fragment (denoted GC3) was isolated as a difference between a human breast cancer cell line K151 (tester) and a normal cell line (driver) from the same patient. GC3 proved to be a fragment of intron 7 of the ELF3 gene which appears to be amplified in the K151 breast cancer cell line. The ELF3 gene belongs to the ETS family of transcription factors which are frequently altered in several types of cancer. This intron fragment of the ELF3 gene was expressed in human breast cancer cell lines and 4 of 6 breast cancer tissues but not in matched normal cell lines and normal tissues after testing by reverse transcriptase PCR (RT-PCR). Genomic DNA contamination of RNA isolates was excluded by DNase I and RNase digestion analysis. mRNA of GC3 was detected in both nuclear and cytoplasmic RNA fractions of breast cancer cell lines, indicating that intron containing ELF3 mRNA had not been properly spliced prior to export to the cytoplasm of these cancer cells. These findings were verified using the 5' and 3' rapid amplification of cDNA ends (5' RACE and 3' RACE) procedures to search for cDNA sequences in RNA from these cancer cell lines. This revealed the presence of partially unspliced ELF3 mRNA and fully spliced ELF3 mRNA in the same breast cancer cell line. Sequence analysis confirmed that GC3 was indeed retained in cytoplasmic mRNA. Partially unspliced ELF3 mRNA contained introns 4, 5, 6 and 7 without any nucleotide mutation at intron/exon splice junction borders. Fully spliced 1959 bp ELF3 mRNA showed a different 5' UTR from the published ELF3 mRNA, and was predicted to encode a 371 amino acid protein which shared 98% homology to the ELF3 protein sequence. This is the first report of intron retention of ELF3 and/or the pathological appearance of both spliced and unspliced cytoplasmic ELF3 mRNA present simultaneously in human breast cancer cells. The finding that intron 7 of the ELF3 gene is present in breast cancer cells lines and tissues (4 of 6 tested) from breast cancer and not in normal autologous breast tissue

-33-

and cell lines may be very important in the understanding of the pathogenesis of breast cancer.

Introduction

The search for a viral etiology of human breast cancer has been the 5 subject of numerous investigations, especially since the discovery of a transmissible agent in milk causing breast cancer in mice (Bittner, 1942). Representational difference analysis (RDA) is a recently developed technique (Lisitsyn et al, 1993; Hubank and Schatz, 1994) that has been useful in detecting viral sequences and unique genes. It was instrumental in the 10 discovery of herpes virus 8 (Chang et al., 1994), hepatitis virus TTV (Nishizawa et al., 1997) and the novel gene TSP50 (Yuan et al., 1999). Using a modified RDA (mRDA) technique, this study describes the isolation of a DNA intronic fragment of the ELF3 gene in breast cancer cells which appears to be uniquely retained in the cytoplasmic mRNA in breast cancer cells and cell lines.

15 Breast cancer cell lines and matched normal cell lines were developed from malignant effusions. DNA from a cancer cell line was used as "tester" and matched normal cell line DNA was used as "driver" in an mRDA method. Two DNA fragments, denoted GC2 and GC3 unique to the cancer DNA, were found. This report focuses on GC3, a 531 bp DNA fragment. This fragment was found 20 to be within intron 7 (bp7514-8045) of the ELF3 gene (Chang et al., 1997; Oettgen et al., 1997b; Tymms et al., 1997; Andreoli et al., 1997; Choi et al., 1998).

In this study, GC3 appeared as a difference between breast cancer and matched normal cells, and is present in the amplicon and genomic DNA 25 Southern blotting of the cancer lines but not the matched controls. In order to determine whether there was transcription of this GC3 intron 7 area, cytoplasmic mRNA was analyzed by reverse transcription polymerase chain reaction (RT-PCR). Using RT-PCR, cDNA was found to be retaining intron 7. This observation was confirmed by application of the 5' and 3' RACE procedure 30 which revealed an ELF3 cDNA sequence including introns 4, 5 and 6 without

nucleotide mutation at the intron/exon junctions. In addition to the partially unspliced cDNA, a fully spliced 1959 bp ELF3 cDNA sequence was isolated which was identical to the mRNA of ELF3, and predicted to encode a 371 amino acid protein sharing 98% homology to the ELF3 protein. Although the coding 5 sequence was almost identical to the published ELF3 gene, the 5' UTR was different, and extended from 4976 to 5006 instead of from 4777 to 4888 of the ELF3 nucleotide sequence (Tymms et al., 1997).

Intron retention of the GC3 intronic area was found in the cytoplasm of breast cancer cell lines and in breast cancer tissue and appears as a pathological 10 defect which may be unique to breast cancer. Unspliced ELF3 mRNA in breast cancer suggests altered regulatory pathways in the splicing of ELF3 mRNA. In eukaryotic cells, most cytoplasmic mRNA does not contain unspliced sequences as unspliced nuclear mRNA is enzymatically destroyed in the nucleus after splicing (Darnell et al., 1997; Cramer et al., 2001; Hide et al, 2001; Stutz et al., 15 1998; Krug, 1993; Hastings and Krainer, 2001). However, retroviruses (Cullen, 1998; Flint et al., 2000; Favaro and Arrigo, 1997) and some herpes viruses (Cheung et al., 2000; Ellison et al., 2000; Kienzle et al., 1999) are able to induce intron retention in mRNA which enables them to use this mechanism to produce different viral proteins (Cullen, 1998; Flint et al., 2000; Favaro and 20 Arrigo, 1997) and allows them to alter the splicing of cellular proteins important to the function of the virus (Cheung et al., 2000; Ellison et al., 2000). The finding of intron retention in the ELF3 gene in breast cancer cells may be an important finding in understanding the pathogenesis of breast cancer and suggests a mechanism to search for a viral cause of breast cancer.

25 **Materials and Methods**

Cell Lines. Paired human breast cancer and normal cell lines were established from malignant breast cancer effusions. All effusions were obtained from patients with metastatic breast cancer using an investigational review board approved protocol. Briefly, mononuclear cells from effusions were 30 isolated and cultured in RPMI media (GIBCO-BRL) with 20% fetal bovine serum

-35-

(FBS)-at 37°C in a 5% CO₂ atmosphere. After 2 to 3 days, non-adherent cells were transferred to another flask and cultured separately. Cells were monitored regularly for morphology and growth characteristics. The adherent cells were passed by trypsinization and diluted 1:2 when adequate growth appeared. Non-

5 adherent cells were also passed at the same dilution. When independent and continuous growth sustained recurrent passage, cytogenetic analysis was performed in the Cell Genetics Laboratory of North Shore University Hospital using standard cytogenetic techniques, which measure chromosome number and morphology. Expression of epithelial glycoprotein (EGP2), a cell surface

10 glycoprotein present in most epithelial cells and tumors, and cytokeratin-19 (K19), a primitive keratin expressed by all epithelial cells, was assessed using RT-PCR as described (Gazdar et al., 1998). MCF-7 human breast tumor cell lines, U-937 human histiocytic lymphoma cell lines and Jurkat human T cell leukemia cell lines were routinely cultured with RPMI 1640 (GIBCO-BRL)

15 supplemented with 10% FBS at 37° C in a 5% CO₂ atmosphere. The MCF-7 human breast cancer cell line, human histiocytic lymphoma cell line (U-937) and the human T cell leukemia cell line (Jurkat) were obtained from the American Type and Tissue Culture Collection (ATCC).

Modified RDA. mRDA was performed as described (Yuan et al., 1999).

20 In brief, two µg of DNA isolated from a breast cancer cell line (K151, tester) and its matched normal cell line (driver) by the QIAamp DNA blood kit (Qiagen Inc.) were cleaved with the restriction enzyme *Hpa*II (10 U/µl; Boehringer Mannheim) in a 50 µl reaction at 37° C overnight. Preparation of tester and driver master amplicons and subtractive hybridization were performed as

25 described (Lisitsyn et al., 1993; Hubank and Schatz, 1994). After a second round of subtractive hybridization/PCR amplification, the difference products were subjected to a 2% agarose gel electrophoresis and purified by a DNA gel extraction kit (Qiagen, Inc.). The purified DNA fragments were cloned in the pPCR-script Amp SK(+) cloning vector by using a PCR-Script Amp Cloning Kit

30 (Stratagene). The inserts from positive clones were amplified and used as

probes in master amplicon Southern blot. The candidate probes were then further tested by human genomic DNA southern blot.

Amplicon And Genomic DNA Southern Blotting. 6 μ g of tester amplicon DNA (K151 cancer cell lines) and driver amplicon DNA (K151 normal cell lines) 5 on 1.5% agarose gel were transferred to a positively charged nylon membrane (Boehringer Mannheim) and immobilized by exposure to UV light. The plasmids containing interesting inserts from RDA were used as templates with T3 and T7 primers for probe labeling using the PCR DIG probe synthesis kit (Boehringer Mannheim). Southern blotting and detection was carried out with 10 the non-radiation Southern Blot detection kit (Genius, Boehringer Mannheim) according to the instruction of the manufacturer. For genomic DNA Southern blot, 5 μ g of genomic DNA from the K151 cancer cell line and normal cell line were digested with *Hpa*II or *Msp*I overnight and then hybridized with the probe by using the same procedure as amplicon Southern blotting.

5' And 3' Rapid Amplification Of cDNA Ends (5' RACE And 3' RACE). A 15 search for cDNA sequences was performed by using the SMART RACE cDNA amplification kit (Clontech Inc.). In brief, total cellular RNA was isolated from K151 and K259 cancer cell lines by using the high pure RNA isolation kit (Roche). Five hundred ng RNA was used for construction of the first-strand 20 cDNA library. For the 5' RACE, the cDNA was synthesized using a modified lock-docking oligo (dT) primer and SMART II oligo primer provided in the kit. For the 3' RACE, cDNA was constructed using a traditional reverse transcription procedure, but with a special oligo (dT) primer provided by manufacturer. The protocol followed the instructions from the manufacturer. The primers used in 25 the SMART RACE procedure are listed in Table 1. The cDNA fragments derived from 5' and 3' RACE were gel purified and sequenced by cloning and sequencing protocol as described.

Table 1: Primers used in Examples

Primer name ^a	Sequence - 5'→3 (SEQ ID NO:)	Position ^b	Tm ^c
GC3 - S	CCTGTCCACTGACTCCAGTG (SEQ ID NO:16)	7722-7741	57
GC3 - AS	ACTTGGCCACAGCATGCAG (SEQ ID NO:17)	7923-7905	57
5 GC3 UPF - AS	ACCAAAGGCCATGCGGAGGCCAGAGAA (SEQ ID NO:18)	7572-7598	67
GC3 UPN - AS	CAACAAACCGCAGTGCCCCAGGAAGCCC (SEQ ID NO:19)	7523-7551	67
GC3 DF - S	GCAGGGCTGGCTGGCCTTGGGTGAGAGG (SEQ ID NO:20)	7943-7970	67
GC3 DN - S	CTTGCAGCGCCCAGAGGCACCCACCTG (SEQ ID NO:21)	8004-8030	67
10 GC3 (1-3) - S	GCTACCTGGCGGAACTGGATTCTC (SEQ ID NO:22)	4819-4843	61
GC3 (1-3) - AS	CGCTTGCCTCGTACTTGTCTTCTC (SEQ ID NO:23)	6240-6216	61
GC3 (3-6) - S	AAGACGCAGGTTCTGGACTGGATCAG (SEQ ID NO:24)	6180-6205	63
15 GC3 (3-6) - AS	TGGGATCCAGGTCCACGTCACITC (SEQ ID NO:25)	7194-7171	63
GC3 (6-8) - S	TCCTCAGACTCCGGTGGAAAGTGACG (SEQ ID NO:26)	7155-7179	63
GC3 (6-8) - AS	CCGGCTCAGCTCTCGTAGGTGATG (SEQ ID NO:27)	8198-8174	63
GC3 (8-9) - S	AGCTCAACGAGGGCCTCATGAAGTG (SEQ ID NO:28)	8065-8089	61
20 GC3 (8-9) - AS	TCCCAGGACGATGGCTGACAATACAC (SEQ ID NO:29)	9352-9327	61
ES31	CCCCAGCCATGTACGTGCTATCC (SEQ ID NO:30)	(β-actin)	
ES33	GCCTCAGGGCAGCGGAACCGCTCA (SEQ ID NO: 31)	(β-actin)	
GC3DD - S	CCTGTGTCCAGGAGTACACTAGATCATC (SEQ ID NO:32)	8569-8596	67
25 INSE - S	AGAGGCAAGGGTCTTACGTTG (SEQ ID NO:33)	8659-8680	62
INSE - AS	TCCCTGGCCTTAAAGTCATGT (SEQ ID NO:34)	8774-8795	62

^aS - sense primer; AS - antisense primer^bNucleotide positions are numbered with reference to ELF3 genomic sequence AF110184 (SEQ ID NO:1)

30 °C

RNA Purification. All RNA isolations were extracted from $1-5 \times 10^6$ exponentially growing cells by using the High pure RNA isolation kit (Roche, Indianapolis, IN) according to the manufacturer's protocol. RNA in the cell lysate was selectively bound to a glass fiber fleece in a microcentrifuge filter tube during DNase I treatment and DNA removal. The bound RNA was purified by washing steps and eluted in 75 μ l nuclease-free water. All RNA isolates were tested for genomic DNA contamination by PCR amplification before synthesis of cDNA. For RNase and Dnase I digestion analysis, $\sim 2 \mu$ g total cellular RNA isolated from the K151 breast cancer cell line was digested with either 1 μ g of RNase (Roche, Indianapolis, IN) in a total of 200 μ l ddH₂O or 200 U of RNase-free DNase I (Roche, Indianapolis, IN) in 200 μ l DNase dilution buffer at 37°C for 20 min. RNase or DNase I was then inactivated by incubation at 70°C for 10 min. The RNA in this mixture was then isolated using the same RNA isolation procedure as described. The RNA was eluted in 15 μ l ddH₂O. The RNA was quantified by measuring the absorbance at 260 and 280 nm ($A_{260/280}$) and its integrity was verified on a formamide-agarose gel.

Separation Of Nuclear And Cytoplasmic RNA. RNA was extracted from the nuclear and cytoplasmic fraction of various cell lines. Cells ($\sim 5 \times 10^6$) were washed with ice-cold phosphate-buffered saline (PBS) 3 times and then disrupted with 375 μ l lysis buffer (0.5% NP-40, 20 mM Tris-HCl, 100 mM NaCl, 5 mM MgCl₂, 1 mM dithiothreitol, and 1000 U of RNasin per ml) for 5 min on ice. This preparation was then gently centrifuged at 2000 rpm for 2 min. The pellet, which consists of nuclei, was resuspended in 200 μ l of PBS for nuclear RNA isolation. The cytoplasmic enriched supernatant was centrifuged for another 2 min at 12,000 rpm to remove any contaminating nuclei. The supernatant was used for cytoplasmic RNA isolation. The RNA was then purified from the separated cytoplasm and nuclear fractions by using the same protocol as for total cellular RNA isolation.

RT-PCR And DNA-PCR Analysis. Before cDNA synthesis, all RNA isolates were tested for the presence of genomic DNA contamination by using β -actin primers to assure that there was no genomic DNA contamination in the RNA isolates. β -actin primers (ES31: 5'-CCCCAGCCATGTACGTTGCTATCC-3' [SEQ 5 ID NO:30] and ES33: 5'-GCCTCAGGGCAGCGGAACCGCTCA-3' [SEQ ID NO:31]) were prepared to amplify a 394 bp fragment β -actin expressed gene in the same PCR conditions as GC3 primers which are listed in Table 1. cDNA was synthesized from purified total RNA, nucleic RNA or cytoplasmic RNA at 42° C for 30 min in the presence of oligo d(T)16 primer with MuLV-reverse transcriptase by using RNA PCR kit (Perkin Elmer). PCR amplification (25 μ l) was performed in PCR buffer containing 0.2 μ M of each primer, 2.5 μ l of the first-strand cDNA samples or 10-50 ng of DNA (for PCR), 200 μ M each of deoxynucleoside triphosphate (dNTP) and 2.5 U of Platinum Taq DNA polymerase (Gibco). When the PCR products were used for sequencing 10 purposes, reading proof PWO DNA polymerase (Roche) mixed with AmpliTaq DNA polymerase (Perkin Elmer) (1:5 ratio) was used. The touch down PCR was used to improve the specificity (Hastings and Krainer, 2001; Cullen, 1998). The conditions of touch down PCR were as follows: initial denaturation was 15 carried out at 94°C for 3 min, then followed by 10 cycles, each consisting of 20 denaturation at 94° C for 1 min, annealing at 5° C higher than actual primer annealing temperature for 1 min, extension at 72°C for 1 min, and then followed by 25 cycles, characterized by denaturation at 94°C for 1 min, annealing at actual primer annealing temperature for 1 min, and extension at 25 72° C for 1 min. A final extension was carried out at 72° C for 10 min. The amplified products were separated by electrophoresis on 2% agarose gels containing ethidium bromide in TAE buffer (40 mM Tris-acetate, 1 mM EDTA). The gel was photographed under UV light with Polaroid 677 film. The primers in PCR and RT-PCR reactions in our study were designed by Gene Runner 3.0 (Hasting Software, Inc.) based on the ELF3 gene sequence in GenBank 30 (AF110184) (SEQ ID NO:1) and listed in the Table 1.

-40-

DNA Sequencing. The DNA fragments from RDA, and the cDNA fragments from 5' RACE and 3' RACE were cloned in PCR-Script Amp SK(+) cloning vector by using the PCR-Script Amp Cloning Kit (Stratagene). Plasmids were purified by the Bio-Rad Plasmid Miniprep Kit, and sequenced by T3 and 5 T7 primers in both directions. The DNA fragments from the PCR reaction were diluted 1:10 with dH₂O and sequenced with primers used in the PCR reaction. Sequencing was done at the North Shore University Hospital (New York) DNA Sequencing Facility using an ABI Prism 377 DNA Sequencer. Nucleotide and protein BLAST of the National Center for Biotechnology Information was used 10 to searching for homologous sequences (Altschul et al., 1990; Gish and States, 1993; Altschul et al., 1997).

Breast Cancer Tissue and Normal Tissue Samples: cDNA prepared from breast cancer biopsies and normal tissue from the same patient are described in Yuan et al. (1999) and provided by Dr. H.P. Xu.

15 Results

Establishment Of Human Breast Tumor And Matched Normal Cell Lines. Paired human breast cancer and normal cell lines were established from effusions of patients with breast cancer. After 8 months in culture, adherent cells (denoted K151) showed normal myofibroblast cell morphology with 20 normal chromosomes in cytogenetic analysis. K151 non-adherent cells became partially adherent and showed morphologically malignant characteristics. Malignant cells revealed polyploidy. Cytogenetic analysis revealed two extra chromosome 1 copies, as well as numerous unassigned small chromosomal fragments. These cells expressed both EGP2 and K19, while the K151 25 myofibroblast cell line only expressed K19. These two cell lines are referred to as the cancer cell line and the normal cell line in mRDA analysis. Using the same method, breast cancer cell lines denoted K234 and K259 were established and used for characterization of the DNA fragments isolated from modified RDA of K151.

Isolation Of A Highly Amplified DNA Sequence GC3 From Human Breast

Tumor Cell Lines By mRDA. The DNA isolated from K151 breast cancer cell lines (tester) and matched normal cell lines (driver) were cleaved with the *Hpa*II enzyme and applied to the modified RDA protocol. After two rounds of

- 5 DNA amplification/subtraction and PCR amplification, different products (DP2) were isolated from breast tumor cell lines. The gel purified DP2 fragments were cloned into pPCR-script AMP SK(+) cloning vector and amplified as described. Among 21 clones, 9 clones had different size DNA fragment inserts defined by restriction enzyme digestion. These were used as probes for amplicon Southern blotting. The clones which hybridized only to tester amplicon (cancer) and not to driver amplicon (normal) were sent for sequencing. The nucleotide BLAST search showed that two clones denoted GC2 and GC3, encoded the ELF3 gene 7677-8045 (368 bp) and 7514-8045 (531 bp) respectively (using the numbering system of SEQ ID NO:1). The nucleotide BLAST search against
- 10 15 GenBank Human Expressed Sequences Tags Database (EST) revealed that 365 bp of our GC3 is 98% homologous to a sequence tag of human cDNA (accession number BG960569) derived from the Human Cancer Genome Project and this sequence is located within intron 7 of the ELF 3 gene from nt 7514 to 7878.

The DNA fragment of GC3 had CCGG on both ends (SEQ ID NO:11).

- 20 The 5' terminus is located in a CpG island within intron 7 and the 3' terminal extended to the 5' position at 35 bp of exon 8 of the ELF3 gene. We focused our attention on the larger GC3 DNA fragment. To confirm the difference observed in the tester and diver amplicons, genomic DNA Southern blotting was carried out by using GC3 DNA fragment as a probe to hybridize to tester and
- 25 driver DNA. The same amount of genomic DNA digested by *Hpa*II and *Msp*I from K151 cancer and matched normal cell lines was applied to Southern blotting. The GC3 DNA fragment only hybridized to the DNA from the breast cancer cell lines, but not to the DNA from the matched normal cell lines, whether *Hpa*II or *Msp*I enzymes were used for digestion (FIG. 1).

-42-

To determine whether the GC3 DNA fragment exists exclusively in our breast cancer cell lines, a sensitive PCR technique was employed. Primers which amplify a 202 bp fragment from intron 7 of the ELF3 gene were synthesized based on the sequence derived from GC3. PCR was carried out on

5 DNAs from 3 paired breast cancer and normal cell lines (K151, K234 and K259). ~200 bp PCR products were produced both in breast cancer cell lines and normal cell lines (FIG. 2). The band appearing in the normal cells of K151 was considerably weaker than that of the cancer cell line (FIG. 2). The result showed that the GC3 DNA fragment in intron 7 of ELF3 selected by modified

10 RDA was not uniquely present in the DNA of the cancer cell lines. Nonetheless this sequence does appear as a difference using the less sensitive Southern blotting and amplicon Southern blotting (FIG. 1). This difference thus appears to be due to amplification of this gene product in the tester and not due to mutation within this gene. RDA can produce a difference this way when a DNA

15 fragment is highly repeated or multiple copies are present in the tester in contrast to the driver (Lisitsyn et al., 1995).

Retention Of GC3 In Cytoplasmic mRNA Of ELF3 Gene In Human Breast Cancer Cells. RT-PCR was performed on the mRNA isolated from paired cell lines (K151 and K234) by using the same GC3 primers. The results showed that

20 GC3 was expressed in the breast cancer cell lines but not in matched normal cell lines (FIG. 3). Sequence analysis of this 202 bp RT-PCR product showed 100% homology to the GC3 sequence defined by GC3 primers. cDNA from six paired human breast cancer and matched normal tissues, provided by Dr. H.P. Xu and prepared as described in Yuan et al. (1999), were also examined for expression

25 of intron 7 with GC3 primers. GC3 was present in the mRNA of 4 of 6 breast cancer tissues, but not in normal tissue (FIG. 4). Expression of GC3 in breast cancer cell lines K151, K234 and most breast cancer tissues indicates that intron retention occurs in many breast cancer cells. In order to exclude RT-PCR products that might have resulted from amplification of contaminating genomic

30 DNA in the preparation of RNA, differential DNase I and RNase digestion was

-43-

performed on the total RNA preparation from K151 cancer cell line before cDNA synthesis. The RT-PCR product showed that GC3 and β -actin was generated in the RNA isolated only after DNase I treatment, but not in the sample after RNase digestion (FIG. 5). This confirmed that GC3 was retained in the RNA

5 fraction of the cells and was not there as a result of genomic DNA contamination in our RNA preparation prior to reverse transcription. To elucidate whether GC3 is retained in the cytoplasmic mRNA of the breast cancer cells, RNAs were purified from nuclear and cytoplasmic fractions prepared from the K151 and the MCF-7 human breast cancer cell line, from the human

10 histiocytic lymphoma cell line (U-937) and the human T cell leukemia cell line (Jurkat). cDNA was prepared from these RNAs, and β -actin and GC3 primers were used to detect normal exonic β -actin and abnormal intronic GC3. The same GC3 and β -actin primers were used on the RNA prepared prior to preparation of the cDNA from these cells to rule out any genomic DNA

15 contamination prior to reverse transcription. In an RT-PCR reaction, ~200 bp GC3 products were produced in the nuclear and cytoplasmic RNA of both the K151 and MCF7 breast cancer cell lines (FIG. 6). GC3 was also weakly produced in the nuclear RNA but not in the cytoplasmic RNA of the U-937 cell line. There was no GC3 RT-PCR product in either the nuclear or cytoplasmic

20 RNA from the Jurkat cell line. No GC3 or β -actin amplification occurred in any nuclear or cytoplasmic RNA samples prior to the reverse transcription step, excluding any genomic DNA contamination in the RNA isolates. The positive β -actin results in the RT-PCR reaction demonstrated the integrity of the RNA and assured that equal amounts of RNA were present in each sample (FIG. 6).

25 mRNA was further purified from all cytoplasmic and nuclear RNA extracts by oligo (dT)₂₀ coated magnetic beads. This mRNA was then subjected to RT-PCR and the cDNA was tested with GC3 and β -actin primers. The same results were obtained with this method of RNA purification. GC3 amplification was seen only in the breast cancer cell lines K151 and MCF7 but not in U937 and Jurkat

cell lines (data not shown). These results confirmed that GC3 is retained in the cytoplasmic mRNA of human breast cancer cells.

Presence Of Partially Unspliced ELF3 mRNA Sequence In Human Breast Cancer Cell Lines. To verify the RT-PCR results and determine that GC3 is retained in cytoplasmic mRNA of breast cancer cells as part of intron 7 of ELF3, the RACE technique was used to determine the cDNA sequence of ELF3 gene. RNA was extracted from K151 and K239 cell lines as described above. After RNA extraction, RNA preparations were screened to assure the absence of genomic DNA contamination using PCR amplification with GC3 primers as shown in FIG. 5A. After establishing the 3' and 5' RACE cDNA libraries, GC3 was confirmed to be present in these libraries using the GC3 primer (FIG. 7). When GC3 UPF (SEQ ID NO:18) and GC3 UPN (SEQ ID NO:19) were used as the first primer and nested primer, respectively, in our 5' RACE experiments, an ~1000 bp DNA fragment and an ~300 bp DNA fragment were produced in the K151 cDNA library, and ~400 bp and ~100 bp DNA fragments were produced in the K259 cDNA 5' RACE library (FIG. 8). The ~1000 bp DNA fragment from the K151 5' RACE was gel purified and cloned. All nine positive plasmids containing this DNA fragment were selected. Three of these were sequenced. The sequence from 2 of the 3 sequenced positive plasmids showed 100% homology to 1002 bp of the ELF3 genomic DNA sequence (AF110184) from 6550 to 7551 (SEQ ID NO:12) which contains the entire intron 4, 5, and 6 and 71 bp from the 5' end of intron 7 (FIG. 9). All intron/exon splice junction borders conform with the splice site consensus G/GT...C/AG rule without any single nucleotide mutation. The third sequenced clone had 100% homology to the normal cDNA sequence of ELF3 which contains exon 1 to exon 7 without any intron retention.

When GC3 DF(S) (SEQ ID NO:20) and GC3 DN(S) (SEQ ID NO:21) were used as the first primer and nested primer in the 3' RACE experiments, an ~1000 bp DNA fragment was produced in both K151 and K259 cDNA 3' RACE libraries (FIG. 8). The product from K151 was gel purified and cloned.

-45-

Sequence analysis revealed all the sequences had normal cDNA of ELF3 which contained properly spliced exon 8 and exon 9, 3' UTR and a polyA tail. In order to demonstrate GC3 (as part of intron 7) retention in the ELF3 mRNA, 5' RACE was pursued with GC3 primers. The sequence analysis showed homology to the 5 ELF3 genomic sequence from 7270 to 8198, which contained the entire intron 7. The sequencing results indicated GC3 was retained as part of intron 7 of ELF3 in the mRNA pool. Additionally, introns 4, 5, 6 and 7 were retained in their entirety in the ELF3 mRNA from breast cancer cell line K151. The 5' RACE and 3' RACE results from the breast cancer cell line K151 is summarized in FIG. 10 9.

Presence of Normal ELF3 mRNA In Human Breast Cancer Cells The fully spliced mRNA from our breast cancer cells provided herein as SEQ ID NO:2 is 1959 bp and is predicted to encode a 371 amino acid protein (SEQ ID NO:4), which shares 98% homology to the ELF3 protein sequence. Even 15 though the coding sequence (CDS) was 98% homologous to the published cDNA sequence of the ELF3 gene (Oettgen et al., 1999; Oettgen et al., 1997a; Brembeck et al., 2000; Lisitsyn et al., 1995), the 5' UTR was different and was derived from 4876 to 5006 instead of 4777 to 4888 of the ELF 3 genomic DNA sequence (SEQ ID NO:1). The presence of fully spliced mRNA of the ELF3 gene 20 in our breast cancer cells was further confirmed by the sequence analysis of RT-PCR products, in which the PCR reaction was performed on K151 and K259 cDNA libraries prepared for the 5' RACE (FIG. 10). Primers were chosen which spanned intronic areas (Table 1 -GC3(1-3)S and AS (SEQ ID NO:22 and 23); GC3(3-6)S and AS (SEQ ID NO:24 and 25); GC3(6-8) S and AS (SEQ ID NO:26 and 27); GC3(8-9)S and AS (SEQ ID NO:28 and 29). The fully spliced exon 1, 2, 3 (343 bp), exon 3, 4, 5, 6 (460 bp), exon 6, 7, 8 (369 bp) and exon 8, 9 (409 bp) were amplified with four different pairs of primers, indicative of appropriate splicing of introns in these products. The result indicates that fully spliced mRNA of ELF3 constitute much of the ELF3 mRNA. The sequence 25 analysis reveals normal splicing of all 8 introns from mRNA of ELF3. The RT- 30

PCR and cDNA sequence analysis indicated that both partially unspliced ELF3 mRNA which contains intron 4, 5, 6 and 7 and fully spliced normal ELF3 mRNA are present in human breast cancer cell lines (FIG. 10).

Discussion

- 5 Malignant breast cancer effusions were used to obtain normal and cancer cell lines from the same patient in order to find genetic differences between the autologous cell lines. An mRDA technique using the malignant cell lines as a tester and the normal cell lines as a driver was utilized. A 531 bp DNA fragment, denoted GC3 (SEQ ID NO:11), positioned at 7514-8045 in intron 7
- 10 and exon 8 of the ELF3 gene, was obtained as a difference. As the GC3 sequence was normal, amplification of GC3 was felt to be responsible for the difference, as RDA can detect small restriction fragments with different sequences, but can also detect amplified sequences that are enriched by kinetic factors and cannot be completely subtracted by the driver (Lisitsyn et al., 1995).
- 15 Cytogenetic analysis of the malignant line K151 used in the procedure revealed two extra copies of chromosome 1, the site of ELF3. Fluorescence in situ hybridization (FISH) has shown ELF3 amplification in the SK-BR-3 (5 to 6 copies) and BT-474 (4 copies) breast cancer cell lines, which results predominantly from an increase in chromosome 1q number (Chang et al.,
- 20 1997).

As GC3 was assumed to be upregulated in the malignant clone, expression of this area was sought and found by RT-PCR. GC3, as part of intron 7 of ELF3 gene, was retained in the ELF3 cytoplasmic mRNA transcript in breast cancer cell lines and most breast cancer tissues (4 of 6) but not matched normal cell lines and tissues. Great care was taken to exclude DNA contamination as an artifactual cause of the findings. The 5' and 3' RACE procedures were used to confirm GC3 intron sequences in ELF3 cytoplasmic mRNA. These procedures further showed that there was retention of introns 4, 5, and 6 in mRNA, along with fully spliced 1959 bp normal transcripts of mRNA.

This is the first time that transcripts of ELF3 with multiple introns were found to be retained in cytoplasmic ELF3 mRNA in breast cancer. Intron retention in breast cancer cell lines and breast cancer tissue has also not been previously described. Clearly this is a pathological process and distinguishes

5 breast cancer cells from normal cells. These findings indicate that abnormal mRNA processing is involved. Aberrant mRNA processing may take place by a variety of mechanisms, and may cause appropriate effects as well as pathological states. Exon skipping, abnormal splice site selection, and full intron selection have been described (Stutz and Rosbach, 1993; Krug, 1993; 10 Stella et al., 2001; Hellwinkel et al., 2001; Beghini et al., 2000). Intron sequences have been shown to have motifs which can alter gene expression by influencing transcription rate (Matsumoto et al., 1998). Introns may code for independent proteins (Krug, 1993), may extend the coding sequence of an adjoining exon, or may provide alternate translation termination signals 15 (Beghini et al., 2000). The appearance of introns in cytoplasmic mRNA is unusual in eukaryotic cells, though physiologic alternate splicing provides a mechanism for expanding protein expression (Hide et al., 2001). Splice site mutation may slow or prevent intron removal, but these incompletely spliced mRNAs are not transported into the cytoplasm (Stutz and Rosbash, 1998; Krug, 20 1993). Export of mRNA through the nuclear membrane usually requires splicing of all introns (Darnell et al., 1997; Cramer et al., 2001).

A database of aberrant splicing in mammalian genetic disorders has shown that genomic mutation with resultant intron retention is relatively rare (Nakai and Sakamoto, 1994). A nonsense mutation causing exon skipping and

25 intron retention of LKB1/STK11, a Peutz-Jeghers syndrome gene, may contribute to tumorigenesis in a small fraction of malignant melanomas (Guldberg et al., 1999). Intron retention of non-mutated ELF3 (Intron 4, 5, 6, 7) in breast cancer cells and tissue containing multiple normal stop codons excludes alternate splicing as a cause.

-48-

Intron retention associated with cancer cells is seen with the CD44 gene. Intron 9 and intron 18 of the CD44 gene are retained in the cytoplasmic mRNA transcripts in tumors. CD44 is known to be composed of at least 20 exons, ten or more of which can be alternatively spliced to produce various isoforms

5 (Cooper, 1995; Matsumura et al., 1999; Goodison et al., 1998; Yoshida et al., 1995).

While intron retention appears rare in cancer cells it is commonly used by viruses to make more proteins from a simple nucleic acid organization. In HIV-1, the rev protein is able to bind to the rev response element and prevent 10 the splicing out of introns, allowing full transcripts of the HIV RNA to enter the cytoplasm. It protects the viral RNA from intron splicing and helps bind the mRNA to the nucleopore for external transport of unspliced mRNA to the cytoplasm (Cullen, 1998; Flint et al., 2000; Favaro and Arrigo, 1997). In herpes simplex 1, the protein ICP27 acts like Rev to make the cellular gene for 15 α -globin appear in an unspliced fashion in the cytoplasm. ICP27 may act after pre mRNA to prevent degradation of some intron-containing fragments and then help those fragments out of the nucleus through an alternative nuclear export pathway (Cheung et al., 2000; Ellison et al., 2000).

Some viruses have been speculated to cause human breast cancer, 20 including a retrovirus (Ketdar et al., 1984; Moore et al., 1971; Wang et al., 1998; Wang et al., 1995; Pogo et al., 1997; Al-Sumidaie, 1988), a polyoma (Fluck et al., 1996) and a herpes virus (Bonnet et al., 1999). One could speculate that the ELF3 intron retention could be caused by some viral product which acts indirectly on the ELF3 gene similar to the way ICP27 acts on the α - 25 globin gene. The appearance of intron retention of the ELF3 gene could thus be used to search for a potential viral protein which may result in breast cancer.

Example 2. Cytoplasmic Intron Retention And A New Alu Element In The mRNA Of The ELF3 Gene In Peripheral Blood Mononuclear Cells From Patients With Breast Cancer

Example Summary

Example 1 describes the retention of intron 7 of the ELF3 gene in cytoplasmic mRNA in breast cancer tissue and breast cancer cell lines but not in autologous normal breast epithelial cells. That finding, along with retention of 5 introns 4, 5 and 6 of ELF3 and expression of fully spliced ELF3 mRNA was demonstrated using reverse transcriptase PCR (RT-PCR) and by 5'- and 3'- rapid amplification of cDNA ends (RACE). As described in this Example, downstream genomic DNA walking from intron 7 of ELF3 led to the discovery of a new Alu element, termed Alu_{kwd} (SEQ ID NO:13), which was found inserted in an 10 antisense orientation between nt 8762 and nt 8763 of the ELF3 gene (SEQ ID NO:1). This Alu_{kwd} was found to be retained in the cytoplasmic mRNA as a fragment of intron 8 in breast cancer tissues and cell lines similar to intron 7. In order to see if Alu_{kwd} and intron 7 retention occurred in other cells than breast epithelium, peripheral blood mononuclear cells (PBMCs) from breast cancer 15 patients were tested for these gene fragments in the total RNA from these PBMCs. Great care was taken to assure that there was no contamination of the RNA with genomic DNA prior to creation of cDNA libraries. PBMCs from 13 of 28 patients with ductal carcinoma in situ (DCIS) with or without invasion were found to have intron 7 retention while 10 of 28 had Alu_{kwd} retention. All 20 patients with Alu_{kwd} had concomitant intron 7 retention. Three of 25 patients without DCIS but with invasive duct cancer or invasive lobular cancer had intron 7 and/or Alu_{kwd} retention. Only 2/20 PBMCs from normal patients had intron 7 retention while 0/20 normals had Alu_{kwd} retention. The association of retention of intron 7 and/or of Alu_{kwd} with DCIS was highly statistically 25 significant (p value=0.008) using the Chi square test. The presence of intron retention of this epithelium-specific mRNA within PBMCs has not been previously shown. The cause of this unusual intron retention in these cells is not known, but this finding is useful in understanding the pathogenesis of DCIS, and as the basis for an assay to distinguish DCIS from other forms of breast

-50-

cancer. A better understanding of the biology of ELF3 might provide a new target for developing better chemotherapy for breast cancer.

Introduction

In this Example, ELF3 gene walking upstream of intron 7 led to the 5 discovery of a previously undescribed Alu element inserted within another Alu element in a reverse orientation within intron 8 of the ELF3 gene. This Alu, designated Alu_{kwd}, is also found retained in cytoplasmic mRNA in breast cancer cells and breast cancer tissue along with the retention of a fragment of intron 7 which we designate as GC3. These phenomena were explored further using 10 normal cells from breast cancer patients to determine whether there is a general error in ELF3 splicing, and to determine whether this Alu_{kwd} might be linked to the cytoplasmic intron retention discussed in Example 1. Accordingly, we chose to study peripheral blood mononuclear cells from breast cancer patients to determine whether there might be some global defect in splicing of ELF3 in 15 otherwise normal cells from these patients.

This investigation resulted in the finding of intron retention of Alu_{kwd} along with the GC3 fragment of intron 7 in cytoplasmic mRNA in PBMCs from women whose breast cancer pathology indicated the presence of ductal carcinoma in situ (DCIS), with or without invasive carcinoma. This aberrant 20 retention of Alu and intron sequences was seen infrequently in most normal patients without breast cancer, and in other forms of breast cancer in which DCIS was not seen pathologically. The association of intron retention in PBMCs from DCIS patients has not been previously described. This particular form of breast pathology (i.e., DCIS) appears to be a major precursor in the 25 development of invasive ductal carcinoma. The finding of ELF3 gene expression in PBMCs is also a novel finding for this gene that heretofore was believed to be expressed only in epithelial cells and not in lymphoid tissue (Tymms et al., 1997; Chang et al., 1997; Andreoli et al., 1997; Choi et al., 1998; Chang et al., 1999; Oettgen et al., 1999; Oettgen et al., 1997a; Brembeck et al., 2000; Chang 30 et al., 2000).

Materials and Methods

Human tumor cell lines. Human breast cancer and matched normal cells lines (K151, K234 and K259) were established in our laboratory as described in Example 1, and maintained with 20% FBS-1640 media in T75 flasks at 37°C in 5 a 5% CO₂ atmosphere. MCF-7 (human breast cancer), U-937, (human histiocytic lymphoma), Jurkat (human T cell leukemia) and C33-A (human cervical cancer) cell lines were obtained from the American Type and Tissue Culture Collection (ATCC) and routinely maintained in RPMI 1640 (GIBCO-BRL) supplemented with 10% FBS at 37° C in a 5% CO₂ atmosphere.

10 Genomic DNA Walking. DNA was isolated from cells using the QIAamp DNA blood kit (Qiagen Inc.). The Universal GenomeWalker kit (Clontech Laboratories, Inc.) was used for genomic DNA walking based on the instructions provided by the manufacturer. Briefly, genomic DNA was digested by *Dra*I, *Eco*RV, *Pvu*II and *Stu*I overnight and ligated with the adaptor from the kit. The 15 uncloned, adaptor-ligated genomic DNA fragments were used as genomic-walker libraries for polymerase chain reaction (PCR) amplification. Primary PCR used the outer adaptor primer provided in the kit (AP1) coupled with either sense (GC3 DF)(SEQ ID NO:20) or antisense (GC3UPF)(SEQ ID NO:18) primers derived from known sequences for downstream and upstream walking 20 respectively. The primary PCR mixture was then diluted and used as a template for nested PCR with a nested adaptor primer from the kit (AP2) combined with either nested sense (GC3DN)(SEQ ID NO:21) or antisense (GC3 UPN)(SEQ ID NO:19) primers. The GC3 DD (SEQ ID NO:32) primer was used for further down-stream walking in the first and nested PCR reaction. The sequences of 25 the primers are listed in Table 1, in Example 1). Each of the DNA fragments that begin in a known sequence at the 5' end of antisense primers (upstream walking) or the 3' end of sense primers (downstream walking) and which extend into the unknown adjacent genomic DNA were cloned and sequenced as described below.

Sequencing and GenBank searching. The DNA fragments from genomic walking were gel purified by using the Wizard PCR preps DNA purification system (Promega Corp.) and cloned in pPCR-script Amp SK(+) cloning vector by using the PCR-Script Amp Cloning Kit (Stratagene). Plasmids were purified

5 using the Plasmid Miniprep Kit (Bio-Rad Laboratories), and sequenced by T3 and T7 primers in both directions. For PCR product sequencing, the DNA fragments from the PCR reaction were diluted 1:10 with distilled H₂O and sequenced with primers used in the PCR reaction. The sequencing was done at the North Shore University Research Institute (New York) DNA Sequencing
10 Facility using an ABI Prism 377 DNA Sequencer. Nucleotide BLAST of the National Center for Biotechnology Information was used for searching for homologous sequences (Altschul et al., 1990; Gish and States, 1993; Altschul et al., 1997).

RNA extraction. In this study, all RNA extraction was carried out with

15 the High Pure RNA isolation kit (Roche, Indianapolis, IN) according to the manufacturer's protocol. Any co-purified DNA was ultimately digested with DNase I. All RNA isolates were tested for genomic DNA contamination by PCR amplification before reverse transcription to cDNA. Isolation of nucleic RNA and cytoplasmic RNA was performed according to a basic protocol (Ausubel, 1995) with slight modification. Briefly, freshly prepared cell pellets were suspended in 200 μ l of lysis buffer containing the nonionic detergent P-40 for 5 minutes on ice. The lysates were centrifuged at 2000 rpm/min to separate a cytoplasmic fraction (supernatant) and a nuclear fraction (cell pellet). The supernatant containing the cytoplasmic extract was transferred to a fresh tube. 20 25 30 The pellet, which consisted of nuclei, was resuspended in 200 μ l of PBS buffer for nuclear RNA isolation. The supernatant was used for cytoplasmic RNA isolation after further centrifugation for 2 min at 12,000 rpm to further remove any contaminating nuclei. The RNA from the separated cytoplasm and nuclei were prepared by using the same protocol as total cellular RNA isolation. RNAase and DNAase I digestion analyses were performed to assure that there

was no DNA contamination of RNA isolates prior to conversion to cDNA. Approximately 500 ng of total RNA was digested with either 5 µg of RNAase or 200 U of RNAase-free Dnase I (Roche, Indianapolis, IN) at 37°C for 20 min. After incubation, RNAase or DNAase I was inactivated by incubation at 70°C for 5 10 min. The reaction mixtures were subjected to the same procedure as RNA isolation.

Preparation of cDNA by RT-PCR and PCR. cDNA was synthesized from purified total RNA at 42°C in the presence of oligo d(T)16 with MuLV-reverse transcriptase with the Perkin Elmer RNA PCR kit. Eight (8) paired cDNAs from 10 breast cancer tissues and matched normal breast tissues were prepared as described in Example 1. PCR amplifications (25 µl) were performed in PCR buffer containing 0.2 µM of each primer, 2.5 µl of the first-strand cDNA samples or 10-50 ng of DNA (for PCR), 200 µM of each dNTP and 1 U of Platinum Taq DNA polymerase (Gibco). When the PCR products were used for sequencing, 15 reading proof PWO DNA polymerase (Roche) mixed with AmpliTaq DNA polymerase (Perkin Elmer) (1:5 ratio) was used. Primers GC3 S (SEQ ID NO:16) and GC3 AS (SEQ ID NO:17) were used to amplify 202 bp of intron 7 of ELF3; primers INSE-S (SEQ ID NO:33) and INSE-AS (SEQ ID NO:34) were used to amplify a 451 bp sequence of intron 8 of ELF3 if Alu_{kwd} is inserted, or a 20 136 bp DNA fragment if Alu_{kwd} is not inserted (Table 1). Touch down PCR was used in PCR reactions to improve the specificity (Don et al., 1995; Roux, 1995). The conditions of touch down PCR for GC3 and β-actin amplification were as follows: Initial denaturation at 94°C for 3 min followed by 10 cycles each of denaturation for 1 min at 94°C, primer annealing for 1 min at 62°C and 25 extension for 1 min at 72°C, followed by 25 cycles of denaturation for 1 min at 94°C, primer annealing for 1 min at 57°C, extension for 1 min at 72°C and then final extension for 10 min at 72°C. For Alu_{kwd} amplification the annealing temperature was at 64° for 10 cycles and 62° for the following 25 cycles. The amplified products were separated by electrophoresis on 1.5% agarose gels

containing ethidium bromide in TAE buffer (40 mM Tris-acetate, 1 mM EDTA). The gel was photographed under UV light with Polaroid 677 film.

Clinical Material. After informed consent, whole blood was collected in EDTA tubes from breast cancer patients at North Shore Hematology/Oncology Associates (New York), a general medical oncology group practice. They were selected only by a diagnosis of breast cancer and willingness to consent to this study. The patient charts were retrospectively reviewed for pathological reports, staging, and demographic information. All clinical information was obtained without knowledge of the laboratory findings. PBMCs were isolated from whole blood by Ficoll-metrizoate (Lymphoprep, Nyegard, Oslo) density gradient centrifugation. Cell pellets were preserved at -70°C for DNA and RNA isolation. PBMCs from 20 unknown blood donors were purchased commercially.

Results

15 Antisense insertion of a unique 315 bp Alu element within intron 8 of the ELF3 gene. We have shown that a fragment (GC3) (SEQ ID NO:11) of intron 7 of the ELF3 gene appeared as a difference in representational difference analysis (RDA) performed on a breast cancer cell line (tester) and a normal cell line (driver) prepared from the same neoplastic breast cancer
20 effusion (Example 1). More importantly, intron 7 (GC3) was shown to be retained in the cytoplasmic ELF3 mRNA which was demonstrated by RT-PCR, and confirmed by cDNA sequencing. In order to search for any mutation or insertion near the intron 7 area which may have contributed to the retention of this intron in mRNA, genomic walking libraries were constructed from genomic
25 DNA isolated from K151 breast cancer cell lines as described in Materials and Methods. Primers were designed based on the GC3 DNA sequence derived from K151 breast cancer cell lines for up-stream walking (GC3 UPF [SEQ ID NO:18] and GC3 UPN [SEQ ID NO:19]) and down-stream walking (GC3 DF [SEQ ID NO:20] and GC3 DN [SEQ ID NO:21]) (Table 1). DNA fragments from *Stu*I
30 and *Pvu*II digested genomic walking libraries were produced for upstream

-55-

walking. The sequence analysis of the 529 bp DNA fragment from the *Stu*I library showed 98% homology to the ELF3 gene from nt 7022 to nt 7511. The 659 bp DNA fragment from the *Pvu*II library showed 94% homology to the ELF3 gene nt 6892 to 7511. In the downstream walking library, a DNA fragment 5 from the *Dra*I library was predominant. The sequence revealed this to be a 629 bp DNA fragment with 96% homology to the ELF3 gene from nt 8003 to nt 8632. The next 40 bp sequence began with an A-enriched region, without homology to the ELF3 gene. To define this area more extensively, further downstream walking was carried out by using a primer (GC3 DD) (SEQ ID 10 NO:32 located in nt 8569 to 8597 of ELF3. Another ~950bp DNA fragment was produced in the *Stu*I library by this further downstream walking. Sequence analysis revealed that this DNA fragment contained the sequence from nt 8569 to 9228 of the ELF3 gene. However, there was an antisense insertion of a unique 315 bp Alu element (SEQ ID NO:13) (designated Alu_{kwd}) within intron 8 15 between nucleotides 8762 and 8763 of the ELF3 gene which does not exist in the published ELF3 gene sequence deposited by Chang et al. (AF110184) (SEQ ID NO:1). This insertion occurs at the end of a 121 bp Alu region just after a 17 bp repeat from nt 8745 to nt 8762 (Appendix, under SEQ ID NO:13). This insertion is within intron 8 of the ELF3 gene, an area important for the ets 20 transcription regulation function of this gene (Tymms et al., 1997; Chang et al., 1997). The Alu_{kwd} sequence provided as SEQ ID NO:13 is only 85% homologous to any known Alu sequences deposited in GenBank. The genomic walking results and the Alu_{kwd} insertion site results are summarized in FIG. 11.

To determine whether the antisense Alu_{kwd} element insertion also exists 25 in other breast cancer cell lines, breast cancer tissues or normal cells, another pair of primers (INSE-S [SEQ ID NO:33] and INSE-AS [SEQ ID NO:34]) were designed, which amplify a 451 bp DNA fragment in intron 8 of ELF3 where Alu_{kwd} was found, flanked by normal intron 8 sequences, as shown in Appendix, under SEQ ID NO:14. PCR analysis was carried out using these primers on the 30 DNA from breast cancer cell lines K151, K234 and K259, on the matched CD3⁺

-56-

T lymphocytes derived from K234, and on normal donor PBMCs. This 451 bp DNA fragment was produced in all the tested samples. A ~140 bp DNA fragment was also observed, especially in the DNA isolated from K151 cancer cells (FIG. 12). This result suggests that Alu_{kwd} is present both in breast cancer tissue and cultured cells from breast cancer patients, as well as in their normal PBMCs. DNA sequence analysis from the 451 bp PCR products reveals 100% homology to the sequence derived from genomic DNA walking, in which the 315 bp antisense Alu_{kwd} sequence was inserted between nt 8672 and 8673 of the ELF3 gene. There was no difference in the DNA sequence found in the 5 breast cancer cells, matched normal cells and PBMCs. The ~140 bp DNA fragment seen in the K151 cancer cells and some other samples indicated the presence of the ELF3 genomic DNA without the Alu_{kwd} insertion, suggesting heterozygosity in these patient's ELF3 gene with one gene product missing the antisense Alu_{kwd} .

10 15 Retention of Alu_{kwd} in ELF3 mRNA in breast cancer cells. A cDNA library was constructed from breast cancer cell lines and normal cell lines as previously described. This library was screened with primers made from the same Alu primers as in the PCR reaction to see if Alu_{kwd} was expressed in these cells in a fashion similar to GC3 (intron 7) described in Example 1. We included a cDNA 20 library from the well-studied human breast cancer cell line MCF-7 cell. The results are shown in FIG. 13. Alu_{kwd} expression was present only in 4 breast cancer cell lines (K151, K234, K259 and MCF-7) but not in matched normal cell lines.

Contamination with genomic DNA during RNA isolation may have 25 resulted in contamination of our cDNA libraries. Such DNA would be amplified in the highly sensitive RT-PCR technique we used in our study. In order to exclude the possibility that the PCR products might result from amplification of contaminating genomic DNA in our RNA isolates, DNAase I and RNAase digestion was performed on the total RNA preparation from the K151 cancer 30 cell line before cDNA synthesis by MuLV reverse transcriptase. The purified

RNA after digestion was reverse transcribed to cDNA. In these studies, β -actin and Alu_{kwd} amplifications were not detected in the RNAase digested RNA sample, but were present in the RNA sample after DNAase I treatment. This indicates that Alu_{kwd} expression in the breast cancer cell lines was not the result of genomic DNA contamination and that Alu_{kwd} was retained in mRNA isolates from breast cancer cell lines. We also tested for the presence of Alu_{kwd} using the Alu_{kwd} primers in 8 paired cDNAs prepared from human breast cancer tissue and matched normal tissues. The result is shown in FIG. 16. The 451 bp Alu_{kwd} containing DNA fragment was produced in 5 of 8 breast cancer tissues (62.5%), but was not found in the matched normal tissues even though β -actin was expressed equally in all tissues.

To verify that Alu_{kwd} is retained in the cytoplasmic mRNA, RNA was purified from isolated nuclear and cytoplasmic fractions of K151, K259 and MCF-7 human breast cancer cell lines as described in Materials and Methods. 15 Human histiocytic lymphoma cell line U-937, human T cell leukemia cell line Jurkat, and human cervical carcinoma cell line C-33A were similarly analyzed. RT-PCR results showed that the ~451bp Alu_{kwd} -containing PCR product was generated in the cytoplasmic and nuclear RNA of K151, K259 and MCF7, but was present only in the nuclear RNA from C33-A and U937. No PCR product 20 was produced in either the nuclear or cytoplasm RNA from Jurkat (FIG. 17B). The same amount of RNA prepared after DNase digestion was not subjected to reverse transcription but was instead tested by PCR using the Alu primers. There was no amplification of the 451 bp DNA fragment in either the nuclear or cytoplasmic fraction (FIG. 17C). These results indicate that the 451bp Alu_{kwd} - 25 containing intron 8 fragment is retained in the cytoplasmic mRNA of human breast cancer cell lines K151, K259 and MCF7 and is not due to genomic contamination of RNA prior to preparation of cDNA. The 393 bp β -actin DNA could be found in all cDNA samples by RT PCR, demonstrating the integrity of the RNA and showing that similar amounts of RNA were present in each sample 30 (FIG. 17A).

Association of intron 7 and intron 8 Alu_{kwd} retention of ELF3 in PBMCs from patients with ductal carcinoma in situ (DCIS). As retention of intron 7 and intron 8 Alu_{kwd} appeared to be exclusively in breast cancer tissues and cancer cell lines, we explored the possibility that these findings might be

5 extrapolated to the peripheral blood, as a useful marker for breast cancer. cDNA libraries were prepared from peripheral blood mononuclear cells (PBMCs) and these libraries were screened for GC3 [intron 7] retention and for Alu_{kwd} retention. The pathological diagnoses of these patients were unavailable during the analysis of the samples for intron retention. RNA was extracted from

10 these cells as described above, and cDNA libraries were prepared. All RNA isolates were tested for genomic DNA contamination using the GC3 and β -actin primers. Only one sample demonstrated genomic contamination and it was not used in our analysis. Commercially purchased lymphocytes from normal healthy adult donors were similarly analyzed. The cDNA libraries from these

15 cells were tested using both the GC3 primers for analysis of intron 7 retention and the Alu primers for intron 8 Alu_{kwd} retention.

After analysis, charts and records were reviewed to determine the type of breast cancer present and to determine the stage of disease. Pathology reports were used to determine the type of cancer and were read by different

20 pathologists at the time of biopsy and independent of this study. These reports indicated that many specimens were from patients with ductal carcinoma in situ (DCIS) either alone or in the presence of invasive ductal carcinoma (DCIS+/-IDC). Invasive ductal carcinoma (IDC) was sometimes reported without mentioning DCIS. Some patients had lobular carcinoma (ILC) with or without

25 lobular carcinoma in situ (LCIS), and/or DCIS +/-IDC. In 2 patients adequate pathological descriptions could not be found and these samples were not used.

Representative gels are shown in FIG. 15, and a summary of the results is presented in Table 2. In patients whose report indicated the presence of DCIS with or without other forms of invasive cancer, intron 8 Alu_{kwd} retention was

30 seen in 10/27 (37%) while it was present in only 3/25 (12%) patients who did

-59-

not have a pathological description of DCIS. This difference was statistically significant at $p \leq 0.01$ by the chi square test. Alu_{kwd} retention was not seen in any of the 20 normal blood donors (Table 2). The same samples when screened for GC3 retention showed this intron to be retained in 13/27 (48%) of DCIS+/-

5 IDC while it was present in only 3/25 (12%) cancers without a description of DCIS. This difference was statistically significant $p \leq 0.01$. GC3 retention was present in on 2/20 normal PBMCs but these bands were very faint with insufficient DNA to adequately sequence to be certain these represented GC3 DNA. The association of Alu_{kwd} and/or GC3 with DCIS± IDC was statistically

10 different from controls ($p \leq 0.01$). All patients showing Alu_{kwd} retention also showed GC3 retention.

Table 2: Summary of clinical results

	Breast cancer with DCIS related subtype (n=21)	Breast cancer with non-DCIS related Subtype (n=28)	Normal donors (n= 20)
5	GC3 Retention (%) P value	13/27 (48.15%) vs. non-DCIS <0.01 vs. normal <0.01	3/25 (12%)
	Alu retention (%) P value	10/27 (37.04%) vs. non-DCIS =0.05 vs. normal <0.05	0/20 (0%)

The Effect of Addition of Breast Cancer Cells to PBMCs on the Detection of ELF3 intron 7 (GC3). The presence of ELF3 expression in the form of intron retention could be the result of circulating breast cancer cells in the peripheral blood which were detected by our methodology. In order to understand the sensitivity of our detection system, we added 10 fold-increasing concentrations of GC3 expressing K259 breast cancer cells, from 1 cell up to 1×10^6 cells, into 2×10^6 PBMCs that did not demonstrate GC3 or Alu_{kwd} retention. RNA was extracted from each dilution and 2 μ l RNA (between 1-3 ng) was used for cDNA synthesis using methods described. These dilutions were tested for the presence of GC3 using GC3 primers which amplify 202 bp intron 7 of ELF3. As shown in FIG. 19, the correct PCR product was visible with a dilution of 1.0×10^6 to 1.0×10^3 per 2×10^6 PBMCs indicating an ability to detect at least 1 cancer cell in 2000 normal PBMCs. Many of the PBMCs which were tested for GC3 were from women who have been in remission from breast cancer for many years and/or from women who have been on therapy but were not considered to have active metastatic disease. This suggests that the presence of intron retention of GC3 or Alu_{kwd} is not due to circulating breast cancer cells but due to some more basic abnormality, detectable in the PBMCs of women with breast cancer.

Discussion

Using cells, tissues, and cell lines from breast cancer patients, and applying gene walking technology, a unique novel Alu element in the ELF3 gene has been found. The Alu, dubbed Alu_{kwd}, is inserted in a reverse orientation into 5 another Alu within intron 8 between positions 8762 and 8763. Two forms of intron 8 DNA exist in our cancer cell lines. One contains Alu_{kwd} and another without this element, indicating heterozygosity of the ELF3 gene.

Alu_{kwd} appears in cDNA in both human breast cancer cell lines and breast cancer tissue specimens. The presence of unspliced mRNA containing Alu_{kwd} in the cytoplasm of the neoplastic cell lines is not due to genomic contamination of RNA prior to creation of cDNA libraries. The Alu_{kwd} is also not found in normal breast epithelial cells or in a limited number of malignant cells from non-breast derived cell lines. Strikingly, PBMCs from 35.7% of breast cancer patients with DCIS, with or without invasion, express Alu_{kwd} in their PBMCs. A fragment of intron 7 of the ELF3 gene, previously designated GC3, is similarly retained in the cytoplasm of 46.4% of the PBMCs from breast cancer patients with DCIS with or without invasion.

Alu elements are ubiquitous in the human genome, which contains 500,000 to 1,000,000 copies representing 5-10% of the total DNA. They can 20 insert themselves into the genome by using “borrowed” reverse transcriptase (Schmid, 2000). They are generally not found within the coding region but have been found in introns and occasionally in non-translated regions of mRNA (Szmulewicz et al., 1998). Previously thought to be “junk DNA” derived from inactivated sequences, Alu cDNAs can insert themselves into genes where they 25 can interfere with, or alter gene function, by interacting with promoters or enhancers as well as introns and exons. They have been shown to induce alternate splicing in some families with BRCA1 mutation.

It is unclear if Alu_{kwd} interferes with splicing. Alu elements are generally spliced out of the final forms of mRNA. Finding retained Alu_{kwd} in cytoplasmic mRNA of breast cancer cells and tissue, along with the previously described GC3

-62-

fragment of intron 7, evidence of a gross splicing defect is present in the ELF3 gene in breast cancer. The retention of introns 4, 5, 6, 7 and the Alu element in intron 8 also favors this assumption. This defect is not present in all breast cancer cell lines or tissue.

- 5 The expression of ELF3 is generally thought to occur only in epithelial cells. We have shown however that we can find unspliced mRNA of ELF3 which includes GC3 (intron 7) and the Alu_{kwd} element within intron 8 in the PBMCs of patients with breast cancer, especially in those with DCIS with or without invasion, as opposed to all other diagnoses. It was not present in PBMCs from
- 10 most normals or in patients whose pathological reports did not indicate DCIS. Its presence is apparently not due to circulating metastatic cancer cells, as most patients were in remission so it is unlikely that they had >1/2000 cancer cells/normal PBMCs, which is the limit of detection of cancer cells with abnormal intron retention in our system. This is evidence of an important ELF3
- 15 splicing error related to breast cancer. The ELF3 gene appears to be important in DCIS and may be associated with regulation of HER2/neu (Chang et al., 1997).

- 20 The presence of intron retention in the PBMCs of a certain cohort of cancer patients is consistent with a global splicing error in some patients with breast cancer, and may be due to some hidden viral element that interferes with splicing. If a putative virus is responsible in some way for breast cancer, it could be searched for using intron retention or Alu_{kwd} as a marker for its presence, similar to the way reverse transcriptase was used as a marker to find the HTLV1 virus (Poiesz et al., 1980) and HIV-1 (Gallo et al., 1984). These findings open
- 25 up a different approach to the epidemiology of breast cancer and provide new useful tools for the study of this disease.

Example 3. Viral induction of ELF3 mRNA intron retention and Alu_{kwd}.

As established in the previous Examples, ELF3 intron 7 (GC3) and intron 8 (Alu) retention was only observed in certain breast cancer cells and tissues as

well as in peripheral blood mononuclear cells (PBMCs) from about 50% of DCIS breast cancer patients. The hypothesis that a virus, specifically a retrovirus or a herpesvirus, may be involved in the cause of breast cancer has been proposed for a long time. To date no clear cut virus has been discovered although some

5 have tried to implicate mouse mammary tumor virus and possibly EBV as a cause of human breast cancer. Therefore we evaluated whether virus infection could induce ELF3 intron 7 (GC3) retention in a cell line. Establishment of the induction of ELF3 intron retention by viral infection would establish that viral presence, particularly a virus associated with breast cancer, can be investigated

10 by evaluating whether ELF3 introns are retained in mRNA. To this end we performed the following experiments. ,

RT-PCR was performed on RNA extracted from PBMCs of 8 HIV-1 infected patients, PBMCs of 1 HTLV-1 infected patient, and from 1 HTLV-1 infected T cell line. GC3 expression was not observed in any of these RNAs

15 from these retrovirally-infected cells.

We next evaluated whether infection with any of 7 human herpesviruses could induce intron retention, by RT-PCR analysis of GC3 expression in RNA preparations from infected cells. Herpes simplex virus I (HSV1), herpes simplex virus II (HSV2), Varicella zoster virus (VZV), Epstein Barr virus (EBV),

20 cytomegalovirus (CMV), human herpes virus 6 (HHV6) and Human herpes virus 8 (HV-8) were the herpes viruses tested. Separate cultures of a MRC5 cell line were each inoculated with a laboratory strain of HSV1, HSV2, VZV and CMV. When the cytopathic effect (CPE) characteristic for each virus appeared, the infected MCR5 cells were collected, and cell pellets were kept at 90°C. EBV-

25 transfected B cell lines, HHV6-infected cell line HSB2, and HHV8-positive cells from Kaposi's sarcoma cells were also used for this study. Uninfected MRC5 cell lines and HSB2 cell lines were used as normal controls. PCR of the RNAs without reverse transcriptase using GC3 primers, as in the previous examples, was performed to rule out DNA contamination.

-64-

In these studies, GC3 expression appeared only in the RNA extracted from EBV-infected cell lines. To confirm that EBV infection can induce ELF3 intron 7 (GC3) retention, further experiments were performed using EBV strain B95-8 (obtained from ATCC). This strain was used to infect the BJAB cells.

5 BJAB is an EBV-negative B cell line that is also negative for intron retention of GC3. The cell pellets were prepared from EBV-infected BJAB cells at day 2, day 4, day 7, day 9, day 11 and day 14 after infection. BJAB without EBV infection was used as a control.

ELF3 intron 7 retention was produced on all EBV-infected BJAB cells
10 from day 2 to day 14. There was no ELF3 intron 7 retention demonstrated in normal BJAB cell lines without EBV infection. These results indicate that EBV infection can induce ELF3 intron 7 retention in infected cell lines. This would suggest that an EBV-like virus or even EBV itself might play some role in the production of breast cancer. We have demonstrated that the cell lines described
15 in the previous Examples that are derived from breast cancers do not show evidence of EBV infection when tested with appropriate EBV PCR primers. We thus believe that a novel virus may play some role in breast cancer and induce intron retention.

20 In view of the above, it will be seen that the several advantages of the invention are achieved and other advantages attained.

As various changes could be made in the above methods and compositions without departing from the scope of the invention, it is intended that all matter contained in the above description and shown in the
25 accompanying drawings shall be interpreted as illustrative and not in a limiting sense.

All references cited in this specification are hereby incorporated by reference. The discussion of the references herein is intended merely to summarize the assertions made by the authors and no admission is made that

-65-

any reference constitutes prior art. Applicants reserve the right to challenge the accuracy and pertinence of the cited references.

-66-

Appendix - SEQ ID NO:s

SEQ ID NO:1 and SEQ ID NO:3 - From GenBank Accession No. AF110184.

SEQ ID NO:1 - ELF3 gene (annotated) - AF110184 and

SEQ ID NO:3 - human ELF3 amino acid sequence alternative 1.

5 LOCUS AF110184 10772 bp DNA linear PRI 22-JUL-1999
DEFINITION Homo sapiens epithelium-restricted Ets protein ESX gene, complete cds.
ACCESSION AF110184
VERSION AF110184.1 GI:5565858
10 SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 4802 to 9870)
15 AUTHORS Chang,C.H., Scott,G.K., Kuo,W.L., Xiong,X., Suzdaltseva,Y., Park,J.W., Sayre,P., Erny,K., Collins,C., Gray,J.W. and Benz,C.C.
TITLE ESX: a structurally unique Ets overexpressed early during human breast tumorigenesis
JOURNAL Oncogene 14 (13), 1617-1622 (1997)
20 MEDLINE 97275260
PUBMED 9129154
REFERENCE 2 (bases 1 to 10772)
AUTHORS Chang,C.H., Scott,G.K., Baldwin,M.A. and Benz,C.C.
TITLE Exon 4-encoded acidic domain in the epithelium-restricted Ets
25 factor, ESX, confers potent transactivating capacity and binds to TATA-binding protein (TBP)
JOURNAL Oncogene 18 (25), 3682-3695 (1999)
MEDLINE 99318560

-67-

PUBMED 10391676

REFERENCE 3 (bases 1 to 10772)

AUTHORS Chang,C.H., Scott,G.K. and Benz,C.C.

TITLE Direct Submission

5 JOURNAL Submitted (30-NOV-1998) Hematology/Oncology, U.C.S.F., 505
Parnassus Ave., San Francisco, CA 94143-1270, USA

FEATURES Location/Qualifiers

source 1..10772

/organism="Homo sapiens"

10 /db_xref="taxon:9606"
/chromosome="1"
/map="1q32"

misc_feature 34..622

/note="similar to THC 213038"

15 repeat_region 921..1524

/rpt_family="Alu"
/rpt_type=dispersed

repeat_region 2978..3293

/rpt_family="Alu"

20 /rpt_type=dispersed

CAAT_signal 4697..4702

/evidence=not_experimental

TATA_signal 4735..4736

/evidence=not_experimental

25 mRNA join(4777..4888,5311..5481,6139..6360,6526..6618,
6822..6941,7129..7218,7364..7480,8011..8206,9076..9872)

/product="epithelium-restricted Ets protein ESX"

5' UTR join(4777..4888,5311..5318)

exon 4777..4888

30 /number=1

-68-

misc_feature 4785..4901
 /note="putative CpG island"
 exon 5311..5481
 /number=2
 5 CDS join(5319..5481,6139..6360,6526..6618,6822..6941,
 7129..7218,7364..7480,8011..8206,9076..9190)
 /note="epithelial-restricted with serine box; Homo
 sapiens ESX cDNA ORF presented in GenBank Accession
 Number U66894"
 10 /codon_start=1
 /product="epithelium-restricted Ets protein ESX"
 /protein_id="AAD45237.1"
 /db_xref="GI:5565859"
 /translation (SEQ ID NO:3)=
 15 "MAATCEISNFSNYFSAMYSSEDSTLASVPPAATFGADDLVTLSNPQMSLEGTEKA
 SWLGEQPQFWSKTQVLDWISYQVEKNKYDASAIDFSRCDMDGATLCNCALEELRL
 VFGPLGDQLHAQLRDLTSSSSDELSWIELLEKDGMQFQEALDPGPFDQGSPFAQEL
 LDDGQQQASPYHPGSCGAGAPSPGSSDVSTAGTGASRSSHSSDSGGSDVDLDPTDG
 KLFPSDGF RDCKKGDPKHGKRKRPRKLSKEYWDCLEGKKSKHAPRGTHLWEFIR
 20 DILIHPNELNEGLMKWENRHEGVFKFLRSEAVAQLWGQKKNSNMTYEKLSRAMRY
 YYKREILERVDGRRLVYKFGKNSSGWKEEEVLQSRN"
 repeat_region 5773..6059
 /rpt_family="Alu"
 /rpt_type=dispersed
 25 exon 6139..6360
 /number=3
 exon 6526..6618
 /number=4
 exon 6822..6941
 30 /number=5

-69-

```

exon      7129..7218
          /number=6
exon      7364..7480
          /number=7
5      misc_feature 7401..7525
          /note="putative CpG island"
exon      8011..8206
          /number=8
repeat_region 8655..8775
10      /rpt_family="Alu"
          /rpt_type=dispersed
exon      9076..9872
          /number=9
3'UTR     9191..9872
15      polyA_signal 9845..9850
          /evidence=not_experimental
misc_feature complement(9952..10387)
          /note="similar to THC 209689"
misc_feature 10358..10772
20      /note="similar to THC 203540"
BASE COUNT 2486 a 2843 c 2985 g 2458 t
ORIGIN
1 aagcttctta ggcatgtgta tgtgtttc ttgcagggga agcagaagta tacactccg
61 ctgttaccacg caatgtatggg tggcagttagt gtggccaga ccctcgccaa ggagactttt
25 121 gcatccaccc cctcccaagct ccacagcaat gttgtcaact atgtccagca gatcgtggca
181 cccaaaggca gtttagaggct cgtgtgcattt gcccctgcct cttcaggctc tccaggcttt
241 cagaataatt gtttgttccc aaatccctgt tccctgatca acttccatggaa gtttatatcc
301 cctcaggata atctattctc tagcttaggt atctgtgact cttgggcctc tgctctggtg
361 ggaacttact tctctatagc ccactgagcc ccgagacaga gaacctgccc acagctctcc
30 421 ccgctacagg ctgcaggcac tgcagggcag cgggtattct cctccccacc taagtctctg

```

-70-

481 ggaagaagtg gagaggactg atgctcttct ttttcttct tctgtcctt ttcttgctga
 541 ttttatgcaa agggctggca ttctgattgt tccttttca ggttaatcc ttattttaat
 601 aaagtttca agcaaaaatt aagttacgga ttgagtgact attaaatttc ttccaccaga
 661 ggtcctcact gtgttggc aggaaggc actggggag gcccagagaa tgacagtatt
 5 721 ttccctgtc cagggAACAG ccagggtaa ggaggtgggt gtcctacaca tgcatatgaa
 781 aaaaaatatg gcaaaatggc acagctggc cagggaaatg aaaaaggaat agcattccag
 841 ttctccgtga agcagctgaa ttctctatc gcagcagcat tcccattatc tttccatca
 901 ctaagaaaaa aaaatggc gggcacggc gtcatgcct gtaatcccag cactttggaa
 961 ggctgaggcg agaggatcgc ttgagcccag gagtttgaga ccaccctggc caacatagca
 10 1021 ggacttcatc tctacaaaaa aaaaaaaaaa aaaaaaaaaa aagccaggcg tggtggtca
 1081 cgccctgtaat ctcaacactt tgggaggctg aggcaggcaa atcacttgag gtcagaagtt
 1141 tgagaccagc atggccaaca tggtaaaacc ccatctctac tgaaaaaaaaa gatagatgca
 1201 aaaattagcc aggcatggc gtcacaccc ttagttccag ttacttggaa ggctgaagca
 1261 ggagaaaaacac ttgaacctgg gaggtggagg ttgcagtaaa ctgagatcat gccactgcac
 15 1321 tccagcctgg gtgacagagt aagacttctc aaaaaaaaaa aaaaaaaagct gggcgtggtg
 1381 gtgcattcct tgggttcag ctactcagga ggctgaggca ggaggatcac ttgagccaa
 1441 gaggtcaagg ccacagttag tcttggattgt gccactgaac tccagcctga gtgacagagt
 1501 gagaccctgt ctcaaaaaata aaaataaaagt gtcttatgac ttttatcta ccctctgcc
 1561 catgcccaag gtttcactgg gcctcacctg tctttgatcc tagataacta tttgaatggt
 20 1621 aatcaagtaa agtctttaga acttagcact aaattctgat ttccctggcct caacatgggg
 1681 acctaaacag tttagcaatct gggtttggaa gtgggatgag gggagggttg gaagaaatat
 1741 tttagtgttt tcatttgccct ttcttaaata cagggcaccc ctgaaacagg cttagtcgc
 1801 agctctgctc tgcctcgga tttaggttat cgaacaggtt tcctccctcc cctgcacaag
 1861 ggttggaaat gactcgattt gcttcactc agcaagagca agggactagt ggtgaccaag
 25 1921 tggtagactg gagaggcctc tgccccgtgg cacacagctc caccatcaga gaggtgtatg
 1981 tgggtcatag gtgagggatc tggaggcccg gtatcggaaag agcttcacca ggcactggca
 2041 ttttgacagc aaactgcttc cgtggctt tcaggactgt tcctggcaa tatgttattg
 2101 gcaaggacta ttttagggctt atccagttgt ctccccctct ccccaaccc ttatcttagct
 2161 tatcagtagc tatcttcct tgcctgtac aaaaacctat agcaccaata ggcccagtaa
 30 2221 tcatgaaggg tcagtgcaag gaaaggctgg aagcccttcc tctaacagcc gtgctgtgac

2281 tccactaact ttgtgggtc tcccattaca tagcgtgggt atcctgagct gtgcagcctg
2341 cctcaactcac cacctggta cctgacagga ctactggatg tgcctgtcct ttgttaggac
2401 attctccat cccaaagatg aggctgtgct gccgtgtggg caagctctgt ggggagaggg
2461 gaggccagtg ggttgtttt gccatcacag aatactggga agccctggc atcctgctcc
5 2521 atagctctct tcaccactat cctggAACt tctccccacc cccatccccca tgcctccaag
2581 gcactgaccc taaatccaag tctttctcac ttatctcaag ctgcccAGCT gttagggattc
2641 cttatctcag ctccatgtca gcggtaggaa agccccaaaga aggcaaggaa gctgacagcc
2701 ttctcatttt tctcgtacat cctccgttcc accccgccccat ccggggagcc ccagccagat
2761 gctttcagg gcagggagca cgtgagcagc cctggggcta gaagccggtt ctccacatt
10 2821 cctgggtgag ggactgggtg gagggtgtgc ctgcctcagg ctccctgggg gaggccccct
2881 gaagggctgg ggaaaatccct actgagcccc aggctctcct gcctgcactg gcccagtgcg
2941 ggggcgggggg ggcggggggga tcctacattt caaaatgcata aaaatctaga tatgggctgg
3001 ggcgcgttagc tcatgcctgt aatcccagca ctttggagg ctgaggcagg cagatcatga
3061 ggtcaggaga tcgagtcctat cctggctaaac atggtaaaac cccgtctcta ctaaaaatac
15 3121 agaaagccgg gcarggcagc gggcgccgt aatccagct actcgaaag ctgaggcagg
3181 agaatcgctt gaaccacga gtcagaggtt gcagttagca gatatcacgc cactgcactc
3241 caacctggc gacagagcga gactccaccc caaaacaaaa taaacccaaat actagatctg
3301 gaagagatct tagggattat taaattcaga caacccattt tttatagat gggaaacaa
3361 gcacagactc caagggcttc atccaaagatc acacaggcgt agatgctggc tacaagtctc
20 3421 ctgcctcaac cacctgtatt accccattca gggctcaag aagggtctat aagacactat
3481 ccattgttt tcgggtgag tccatagaga caaccacaga catggggac tctgcccaca
3541 gggaaaggcaaa gggctctggc catggagctg gatggaaaga ctctgaagcc cgaagacatt
3601 gaatccctgtc cagggaaaga gcgagggttt ttttacaac acacctgcac acctggatgt
3661 gaatctcagc tccacccctt caccaactct gtgtggctg ggcaagccat tctaaggaa
25 3721 ccctccacac tgcaactttc atgtctataa aatggaaata accatgcatt cttacagga
3781 cttttttgggt gtgaggatta aatgagagaa tatgttggaa agtgcctgggt aaatataat
3841 atactatgca ttcccttc tttgaatgac gtgaccagg tagtcaggct tctgaccact
3901 agagggcagc agaaggtaact ggaaaactgg gcccgtgaa ccagagatta gatggggtcc
3961 agagagcagg gatgaactta cccgtgtggta ttctggcaac tccggcaggagg agggctccag
30 4021 caggcgctga ggaaagaact ttcaagcaga gcccggcttc ttcaggagcgt actgcagcaa

4081 ccctgatgt tggatggagt ccaggcaggt gatggtagtg aagaccctgc caacagagt
 4141 ggcgcgtggag aaggagccct ttagtgggga ccctggggcc acgactaggc tggcaggccc
 4201 agccagcacc aattaatcca ttagtattgc ccagcatgta gcctggagca cttccagcc
 4261 cctggccaga gtcctgggtg ttctggaaa aaccctaaa cctagtaact cctctcccta
 5 4321 ctaggcctct ttgttgcgtga atctctggaa tttaggggcc agcagcttc tgactcaggt
 4381 cagccagggg ttcatgttcc ctcaactgccc ctccccctgc ctggccatc tctggcctgg
 4441 cccctggag gaatttctg ggccagaggg cagccgaaag cacagatgcc cacccca
 4501 acgttcccgc cacctgccc ggccagtgcc ccgtgccaa ccccaagaggg tgccggatga
 4561 cagactctga caatcattaa accagccggg cctgatttcc cagcaactgcc tgctaagatc
 10 4621 cgggccaagt ggcactgaat atgcaaatca cctggggcca ggagcccaatg ctaaaggcca
 4681 ggaaatcccc tccatccaaat gagacaccag ctcagggtac tgccggggac acactataaa
 4741 gcccctgagct cagggaggag ctccctccag gctcta **START mRNA**> ttta
 gagccgggta ggggagcgc
 4801 gcggccagat acctcagcgc tacctggcg aactggattt ctctccgc tgccggcctg
 15 4861 cctgccacag ccggactccg ccactccg **INTRON1**> gt aggattcccc gcctgtcatt
 ccctagccca
 4921 gctcttggga aactgcagag gggtccagag gatttgcagt tctgaacctg cacactccag
 4981 tcttaggatct ccgagcaaga gcgttaggtgt cctgagggtc aaagaacaga gagagattgt
 5041 ctctgggaag gcagaatggc catgacgccc ctgtctggc tccaggccc cagagatctg
 20 5101 aggagggaaag cccagctgga ggctcctgtg gtccctccct ggtctgagat ttggagcc
 5161 ttcttgaaga gacgggttcc gcagagttgc tgatcttcc tccctgggg gctactcttgc
 5221 cccagggttt ggcaaagcag agtagctggg agtgtaaaggaa gaggaccctc gtccctcac
 5281 caacctcatc ctctcccc ctacccacag **EXON2**> gtagcctc **START CDS**> at
 ggctgcaacc tgtgagatta
 25 5341 gcaacattt tagcaactac ttcaagtgcga tgcgtacagctc ggaggactcc accctggcc
 5401 ctgttcccc tgcgtccacc ttggggcccg atgacttggt actgaccctg agcaaccccc
 5461 agatgtcatt ggagggtaca **INTRON2**> ggtgggttc agcgggggtgg gatggggcac
 ggagtgggag
 5521 acagatccat ctaagggcct gtagacaaa tggggaaata ggcaggaggagg agggtctcta
 30 5581 ggcaaattcc agggctagag gctgagactt agtgcgtgggat ttgtggggct

-73-

5641 gtgacaggca gagggagggtg tcagataccca ggacaagggt gttgtaatg ctacccctg
 5701 cccctactct tgggatggct ccaagggtcg aggtgtaat ccccagtgtg ctccaggaat
 5761 ggggctgtgt gggctggag tggctggctca cgccgttaat cccagcactt tgggaggctg
 5821 agctgagcgg atcacctgag gtcaagagtt cgagaccagc ctagccaaca tggtaaaacc
 5 5881 ccgtctctac taaaaataca aaaaaaaatt tatcccagcg tgggtgggtggg cacctataat
 5941 cccagctact ggggaggctg acgcaggagt atcgctgaa cctgggaggt ggagggttgc
 6001 gtgagccgag attgtgcat tgcacccca cctaggtgac aggagtgaga ctccatctca
 6061 aaaaaaaaaa aaaaaatggg gctgttaaggt ctgctgggtg gcctgagctg agcctgttc
 6121 cctgcctggc cttgcag **EXON3>** ag aaggccagct ggttgggga acagccccag
 10 ttctggtcga
 6181 agacgcaggt tctggactgg atcagctacc aagtggagaa gaacaagttac gacgcaagcg
 6241 ccattgactt ctcacgtgt gacatggatg gcgcacccct ctgcaattgt gcccttgagg
 6301 agctgcgtct ggtttggg cctctgggg accaactcca tgcccagctg cgagacctca
 6361 **INTRON3>** gtgagtccag gccctggag gctggggagc agtccacat gttgagctga
 15 gtcgagttca
 6421 gtgtggccgt aggccaggccc tggagctctg ggccagctgc acagccagag agagcccttg
 6481 agggagggat tagggagtg tgacccttcc ttcccttcgt gtcag **EXON4>** cttcc
 agctcttctg
 6541 atgagctcag ttggatcatt gagctgctgg agaaggatgg catggcccttc caggaggccc
 20 6601 tagacccagg gcccttg **INTRON4>** gt gagaacccgt ttctcccttc cttccccagc
 ctgtcttgc
 6661 ccatccctgc ccctcacag agtgcttagag atgacccttcc cccagactt ttccctccct
 6721 caattagaaa aattgcagca ggtcatcaga cccatggca gcatcacctg tccctggctg
 6781 gtccctgag ccctctgtga gtttcacccct cctttccca g **EXON5>** accagggca
 25 gcccctttgc
 6841 ccaggagctg ctggacgacg gtcagcaagc cagccctac cacccggca gctgtggcgc
 6901 aggagccccc tccctggca gctctgacgt ctccaccgca g **INTRON5>** gtgagagct
 ctctctggc
 6961 cacaaccccttcc cttccccgaa gtgtcccttg ttccctctgg ctccacgcac cataactcag
 30 7021 gccttctggc aggaacagga acaggctggg aagtgtgtcc ttagagccag cagcgtgggtt

-74-

7081 gaacagaagg tggccggca ggggacttac tctgaccccg ccccccag **EXON6**> gg
 actggtgctt

7141 ctggagctc ccactcctca gactccggtg gaagtgacgt ggacctggat cccactgatg

7201 gcaagctt cccagcg **INTRON6**> gt gagtcgaggg aggtcccaa gagggcgcc

5 cattttagcaa

7261 tgcacagggg gcccggctct tcctgcagcc tttcctgta gaggggctac tctccctaac

7321 tccccctcttg cccctccttg accttccacc accgtccccca cag **EXON7**> atggttt
 tcgtgactgc

7381 aagaaggggg atcccaagca cgggaagcgg aacgaggcc ggcccccggaaa gctgagcaaa

10 7441 gagtaactggg actgtctcga gggcaagaag agcaagcacg **INTRON7**> gtgagctccg
 ggggcacgtg

7501 ggtccctccct gcgcggggct gaggcggttc ctggggcact gcgggttgtt gcaggtatcc

7561 cttctccctgt tttctctggc ctccgcatgg ctttggtaa ggctgtgcac aagctggggg

7621 ctctatggta tcggtcacca cctaattgca gagcctggct tggtggcct ggagaggagg

15 7681 aggaataag gctcccagtgg gaggagctcat ggtaccagag tcctgtccac tgactccatg
 7741 gtccctgtcca ctgactccag ttctctctgc acttggccac tgtccctgccc tctggacac

7801 cctcaatgtg aggaggcagc tgggggtct taggtgggct gaggagaaaa gcagtcaactg

7861 cagtaccgc acagagggca ctgcggggc tctggagagg cttgctgcac gctgtggcca

7921 agtcagcagt gcactggggc gggcagggtt ggctggcctt gggtgagagg ggacacctgg

20 7981 atggcaaaact gatggaggct ggccctgtcag **EXON8**> cgcccagagg cacccacctg
 tgggagttca

8041 tccgggacat cctcatccac ccggagctca acgagggcct catgaagtgg gagaatcggc

8101 atgaaggcgt cttcaagttc ctgcgtccg aggctgtggc ccaactatgg ggccaaaaga

8161 aaaagaacag caacatgacc tacgagaagc tgagccggc catgag **INTRON8**> gtga

25 gctggcgcc

8221 aggaccctca cgatacagcc ggacatgggg acaggcgctc acactcccac cgccctttt

8281 ctggctgcca ttgggttct tgcaacaggg ctgagtcctt agagtgagga caacatctgg

8341 gttggctac ttcatggatt aaatgacaac atggagaaag tattagcctg gcagacagca

8401 gacacagtgc actttagctca gcagcaacat ttctgtatc gcctgtgagg ctgtccctca

30 8461 ggaaggcacc tggagagtgg gaaagggggc aggagccgtg cccacccagg gcctggcttt

-75-

8521 ctccctcggt aagcacttag gttgttttc tctgggcctc agtttctcc tttgtccagg
 8581 agtacactag atcatcttaa gatcccggtcc agccctaaaa tcatgtactt acttttttt
 8641 tcttttctt tttaaaatag aggcaagggt ctctacgtt gccaggccgg tctcaaactc
 8701 ctggcctcaa atgactctcc tgcctcggcc tctcaaagtg ctgggattac aggtgtgagc
 5 8761 cacgggtcccc agctccctgg ccttaaaagt catgttaattt aatgtatcaga ccccaagtcac
 8821 agccatagga tacaaagaag caaaggcaaa gagccctgtg tcctgggcac ggttacaggc
 8881 cagtgttaggg aaagagcttc tgcttgccag tgtgaagaac agaggagttt aggaagtgtg
 8941 agtcaggctc agcttagtca ggcagagacc agtgggcattt ggttacctgg gggtaacgcg
 9001 ggccaggtgg gcgggctggc agectggggc ccatttcctg ccaaagcacc tctgaccatc
 10 9061 cttctttca cccag **EXON9**> gtact actacaaacg ggagatcctg gaacgggtgg
 atggccggcg
 9121 actcgctac aagttggca aaaactcaag cggctggaag gaggaagagg ttctccagag
 9181 tcggaactga **END CDS** gggttggaac tataccggg accaaactca cggaccactc
 gaggcctgca
 15 9241 aactttcctg ggaggacagg caggccagat ggccctcca ctggggatg ctccagctg
 9301 tgctgtggag agaagctgat gttttgggtt attgtcagcc atcgctctgg gactcggaga
 9361 ctatggcctc gcctccccac ctcctcttgg gaattacaag ccctgggtt tgaagctgac
 9421 tttatagctg caagtgtatc tcctttatc tggtgccctcc tcaaaccctt ttcagacac
 9481 taaatgcaga caacaccccttc ctccctgcaga cacctggact gagccaaggaa ggcctgggg
 20 9541 ggcccttaggg gagcaccgtg atggagagga cagagcagg gctccagcac ttctttctg
 9601 gactggcggtt cacctccctg ctcagtgtt gggctccacg ggcaggggc agagcactcc
 9661 ctaatttatg tgcttatataa atatgtcaga tgtacataga gatctatttt ttctaaaaca
 9721 ttccctccc cactcctctc ccacagagtg ctggactgtt ccaggccctc cagtgggtt
 9781 atgctggac ctttaggatg gggctccacg ctcccttcctc ctgtgaatgg aggcagagac
 25 9841 ctccaataaa gtgcctctg ggctttct a **END mRNA** acctttgtc ttagctacat
 gtgtactgaa
 9901 atttgggcct ttggatcgaa tatggtaag aggttggagg ggaggaaaat gaaggctac
 9961 caggctgagg gtgagggcaa aggctgacga agaggggagt tacagatttc ctgttagcagg
 10021 tgtgggcata cagacacatg gactggctg ggaggcgacg aaaggaagca gctgagactg
 30 10081 ttggagaacg cttacaagac ttcatgcaag caaggacatg aactcagaac actgagggtca

-76-

10141 gaagcatacgtgtcatga caccgcgtga gtgacccgtga ccttgaccaa gtctgtcctg
10201 tttaggactg attttccta ttaggctagg gtttggaccc gatgttctca agatgtctag
10261 aattgcatgg ctggccttgt ggaatagatg gttttgcatt ccagccaagt gtgctgtaaa
10321 ctgtatatct gtaatatgaa tcccaagctt tgagtctgac aaaatcagag ttaggatctt
5 10381 **gtaaaggaaa** aaaaaaaaaaaa caaaacaaaaa tggagatgag tacttgctga
gaaagaatga
10441 gggaaaggagt tggcatttgt tgaaagtata gtcttttct cttttttttaattgcaac
10501 ttttacttta gattnaggag gtcgtgcgca ggtttgttac atgggtatat tttgtgtatgc
10561 tgagcttggg atgcgaatga tcctgtcacc caggtgtga gtatagcacc cagtgaaact
10 10621 gtagtctcat gccaggcaact gtgctagccc actctggctc atttaatcct ctcctaagaa
10681 gagaggagac acagcgtccc catttgacag atgcagaaaag aggttccaca ggtgtgcctt
10741 gattctgtcc taaaaccgtt tcccgaaagc tt

//

SEQ ID NO:2 - ELF3 cDNA and

15 SEQ ID NO:4 - ELF3 amino acid sequence alternative 2
1959 bp full length of spliced mRNA of ELF3 gene in breast tumor cell lines and
predicted amino acid sequence of ELF3 gene. The adenosine at the atg start
codon is considered the number one nucleotide.

-135

20 ctccgcccactccggtaggattccccgcctgtcattccctagcccagctttggaaac
tgcagagggtccagaggattgcagttctgaacctgcacactccagtcaggatctc
cgagcaagagcgtggcctc

1 atggctacaacctgtgagattagcaacattttagcaactacttc
M A T T C E I S N I F S N Y F

25 46 agtgcgtatgtacagctcgaggactccaccctggcctctgttccc
S A M Y S S E D S T L A S V P

91 cctgctgccacccctggggccgatgacttggtaactgaccctgagc
P A A T F G A D D L V L T L S

136 aacccccagatgtcatggagggtacagagaaggccagctggttg
N P Q M S L E G T E K A S W L

181 ggggaacagccccagttctgggtgaagacgcagggtctggactgg

-77-

G E Q P Q F W L K T Q V L D W
 226 atcagctaccaagtggagaagaacaagtacgacgcaagcgccatt
 I S Y Q V E K N K Y D A S A I
 271 gacttctcacatgtgacatggatggcgccaccctctgcaattgt
 5 D F S R C D M D G A T L C N C
 316 gcccttggaggactgcgtctggctttggcctctgggggaccaa
 A L E E L R L V F G P L G D Q
 361 ctccatgcccagttgcgagacacttcagcttttatgag
 L H A Q L R D L T S S S S Y E
 10 406 ctcagttggatcattgagctgctggagaaggatggcatggccttc
 L S W I I E L L E K D G M A F
 451 caggaggccctagaccagggcccttgaccaggcagccctt
 Q E A L D P G P F D Q G S P F
 496 gcccaggagctgctggacgcgtcagcaagccagccctaccac
 15 A Q E L L D D G Q Q A S P Y H
 541 cccggcagttgtggcgaggagccccctccccggcagctctgac
 P G S C G A G A P S P G S S D
 586 gtctccaccgcagggactggactggcttcggagctccactccta
 V S T A G T G A S R S S H S S
 20 631 gactccgggtgaaagtgacgtggacctggatcccactgatggcaag
 D S G G S D V D L D P T D G K
 676 ctctccccagcgtatgggttcgtgactgcaagaaggggatccc
 L F P S D G F R D C K K G D P
 721 aagcacggaaagcggaaacgaggccggccccgaaagctgagcaa
 25 K H G K R K R G R P R K L S K
 766 gagtgctggactgtctcgaggcaagaagagcaagcacgcgccc
 E C W D C L E G K K S K H A P
 811 agaggcacccacctgtggagttcatccggacatcctcatccac
 R G T H L W E F I R D I L I H
 30 856 ccggagctcaacgaggccatgaagtggagaatcgacatgaa
 P E L N E G L M K W E N R H E
 901 ggcgtcttcaagttcctgcgtccgaggctgtggcccaactatgg
 G V F K F L R S E A V A Q L W
 946 ggccaaaagaaaaagaacagcaacatgacatcgagaagctgagc

G Q K K K N S N M T Y E K L S
 991 cgggccatgaggtactactacaaacgggagatcctggaaacgggtg
 R A M R Y Y Y K R E I L E R V
 1036 gatggccggcgactcgtctacaagttggcaaaaactcaagcggc
 5 D G R R L V Y K F G K N S S G
 1081 tggaaaggaggaagaggttctccagagtcggaactga 1116
 W K E E E V L Q S R N *
 gggttggaaactatacccgggaccAAactcacggaccactcgaggcctgc
 aaaccttcctgggaggacaggccaggatggccctccactggggaaat
 10 gctcccagctgtgctgtggagagaagctgatgtttgttattgtcagc
 catcgtcctggactcggagactatggcctcgccctccaccctctt
 ggaattacaAAagccctgggTTTgaactgactttatagcttgcaagtgt
 tctcctttatctggtgccctctcaaACCCAGTCTTCAAACACTAAATGC
 agacaacacacccTTCTTGCAAACACCCCTGGACTTGACCCAAGGAGGCC
 15 ggggaggccctaggggagcaccgtgatgagaggacagagcaggggctcca
 gcacccTTCTTGACTGGCGTTcacccctgctcagtgcTTGGCTC
 cacgggcaggggTCAGAGCactccctaatttatgtgctatataaatatgt
 cagatgtacatagagatctatTTTCTAAACATTCCCTCCCCACTCC
 20 tctcccacagagtgcggactgtccaggccctccagtggtatgc
 ggacccttaggatggggctccagctccTTCTCTGTGAATGGAGGCAG
 agaccccaataaagtgcctctggctttccaaaaaaaaaaaaaaaaaaaa
 aaaaaaaaaa

SEQ ID NO:5 - ELF3 intron 4

25 gtgagaaccgtttctccctcccccagcctgttgcctatccctgcccacagagtgcctagatgacccc
ccccccagacttctccctccctcaattaaaaattgcagcaggtcatcagacccatggcagcatcacctgtccctgg
ctggtccccctgagccctctctgagtttcaccccttcccccag

SEQ ID NO:6 - ELF3 intron 5

gtgagagctctctggccacaacccctcccccgaagtgtccctgtccctctggctccagcaccataactcg
gcctctggc
30 aggaacaggaacaggctggaaagtgtgtcctgagagccagcagcgtggtaacagaagggtggccggcaggg
gacttactctgaccccgccccccag

-79-

SEQ ID NO:7 - ELF3 intron 6

gtgagtcgagggagggtccccaaagagggcgccat tagcaatgcacagggggccggctttccgcagcctttc
ctgttagagggctactctccctaactccctctgcccccttgcaccaccaccgtccccacag

SEQ ID NO:8 - ELF3 intron 7

5 gtgagctccggggcacgtgggtccctccctgcgcggggctgagcggcttcgtgggactgcgggttgtgcagg
atcccttctccgtttctctggccctcgcatggcttggtaaggctgtgcacaagctggggctatggtatcggtc
accacctaattgcagagcctggctgggtcctggagaggaggagggaaataaggctccagtggaggctcatg
gtaccagagtcctgtccactgactccagtgtccactgactccagttctctgtccactgtggccactgtccctgc
ctgggacaccctaattgtgaggaggcagctgggtcttaggtggctgaggagaaaagcagtcaactgcagtac
10 ccgcacagagggcactgcgggtctggagaggcagctgtggccatgcgtggccaaactgatggaggctggcc
ggcagggctggctggccctgggtgagaggggacacctggatggcaaactgatggaggctggccctgcag

SEQ ID NO:9 - ELF3 intron 8

gtgagctggcgccaggaccctcacgatacagccggacatggggacaggcgctcacactccaccgcctttct
ggctgccacttggtttttgcacacaggctgagtccttagagtgaggacaacatctgggtggctacttcatggatta
15 aatgacaacatggagaaagtattagcctggcagacagcagacacagtgcacttgagctagcagcaacattttgt
atcgccctgtgaggcttgcctcaggaaggcacctggagagtggaaaggggcaggagccgtgcccacccagg
cctggctttctcctcggtgaagcacttagtttttctctggccctcagtttctctgtgtccaggagtacactagat
catcttaagatcccgccctaaatcatgtacttacttttttttttttttttttttttttttttttttttttttt
catggcaaggccggctcaaaactctggctaaatgactctcctgcctcggccctcaaaagtgtctggattacagg
20 tgtgagccaccgtgccagctccctggccctaaatgtcatgtatataatgatcagaccccagtcacagccataggat
acaaagaaggcaaaaggccctgtgtccctggcacggttacaggccagtgttagggaaagagacttctgc
ccagtgtgaagaacagaggatgttaggaagtgtgagtcaggctcagttagtcaggcagagaccagtggcatgg
gttacctggggtaacgcggccaggtggggctggcagcctggccatccctgcacacccatgtctgacc
atccttcttccatcccag

25 SEQ ID NO:10 - ELF3 primary transcript - numbering as in SEQ ID NO:1.
ttt gagccggta ggggagcga

4801 gcggccagat acctcagcgc tacctggcgg aactggattt ctctcccgcc tgccggcctg

4861 cctgccacag ccggactccg ccactccg **INTRON1**> gt aggattcccc gcctgtcatt
 ccctagccca
 4921 gctcttggga aactgcagag gggccagag gatttgcagt tctgaacctg cacactccag
 4981 tctaggatct ccgagcaaga gcgttaggtgt cctgagggtc aaagaacaga gagagatgt
 5 5041 ctctgggaag gcagaatggc catgacgccc ctgtctggc tccaggccc cagagatctg
 5101 aggagggaaag cccagctgga ggctcctgtg gtcctccct ggtctgagat ctggagccc
 5161 ttcttgaaga gacgggttcc gcagagttgc tgatcttctt gcccctgggg gctactctt
 5221 cccagggttt ggcaaagcag agtagctggg agtgtaagga gaggaccctc gtccctcac
 5281 caacccatc ctctcccccc ctacccacag **EXON2**> gtagcctc **START CDS**> at
 10 ggctgcaacc tgtgagatta
 5341 gcaacattt tagcaactac ttcagtgcga tgtacagctc ggaggactcc accctggcct
 5401 ctgtcccccc tgctgccacc tttggggccg atgacttggt actgaccctg agcaacccccc
 5461 agatgtcatt ggagggtaca **INTRON2**> ggtgggttc agcggggtgg gatggggcac
 ggagtgggag
 15 5521 acagatccat ctaagggcct gtagacaaa tgggggataa ggcagggagg agggctctta
 5581 ggcaaattcc agggctagag gctgagactt agtgacttag gtgtgggggg ttgtgggct
 5641 gtgacaggca gagggagggtg tcagatacca ggacaagggt ttgtgaatg ctacccctg
 5701 cccctactct tggatggct ccaaggctg aggtgtaaat cccctgttg ctccaggaat
 5761 gggctgtgt gggctggag tggctca cgcctgtaaat cccagctt tggaggctg
 20 5821 agctgagcgg atcacctgag gtcaagagtt cgagaccgc ctagccaaca tggtaaacc
 5881 ccgtctctac taaaaataca aaaaaaaaaatt tatccagcg tggtggtggg cacctataat
 5941 cccagctact gggaggctg acgcaggagt atcgcttcaa cctgggaggt ggaggttct
 6001 gtgagccgag atttgccat tgcacccag cctaggtgac aggagtgaga ctccatctca
 6061 aaaaaaaaaaaa aaaaaatggg gctgtaaagg ctgctgggtg gcctgagctg agccgttcc
 25 6121 cctgcctggc ccttcag **EXON3**> ag aaggccagct ggtggggga acagccca
 ttctggtcga
 6181 agacgcaggt tctggactgg atcagctacc aagtggagaa gaacaagtac gacgcaagcg
 6241 ccattgactt ctcacgtatgt gacatggatg gcccaccct ctgcaattgt gcccttgagg
 6301 agctgcgtct ggtctttggg cctctgggg accaactcca tgccctgtc cgagacctca

gtcgagttca

6421 gtgtggccgt aggccaggccc tggagctctg ggccagctgc acagccagag agagcccttg .

6481 agggagggat taggggagtg tgacccttcc ttcccttcgt gtcag **EXON4>** cttcc

5 agctcttctg

6541 atgagctcag ttggatcatt gagctgctgg agaaggatgg catggccttc caggaggccc

6601 tagaccagg gcccttg **INTRON4>** gt gagaaccctg ttcttccttc cttccccagc

ctgtcttgc

6661 ccatccctgc ccctccacag agtgctagag atgaccctt cccagactt ttccctccct

10 6721 caattagaaa aattgcagca ggtcatcaga cccatggca gcatcacctg tccctggct

6781 gtcccctgag ccctctctga gtttcaccccttccca g **EXON5>** accagggca

gcccctttgc

6841 ccaggagctg ctggacgacg gtcagcaagc cagccctac caccggca gctgtggcgc

6901 aggagccccc tccctggca gctctgacgt ctccaccgca g **INTRON5>** gtgagagct

15 ctctctggc

6961 cacaacctcc ttcccccga ggtcccttg ttccctctgg ctccaggcac cataactcag

7021 gccttctggc aggaacagga acaggctggg aagtgtgtcc tgagagccag cagcgtggtt

7081 gaacagaagg tggccggca ggggacttac tctgaccctcg ccccccag **EXON6>** gg

actggtgctt

20 7141 ctggagctc ccactcctca gactccggtg gaagtgacgt ggacctggat cccactgtat

7201 gcaagcttt cccagcg **INTRON6>** gt gagtcgaggg aggtcccaa gagggcgtcc

catttagcaa

7261 tgcacagggg gcccggctct tccctgcagcc tttctgtta gaggggctac tctccctaaac

7321 tccctcttg cccctcttg acctccacc accgtccca cag **EXON7>** atggttt

25 tcgtgactgc

7381 aagaaggggg atcccaagca cgggaagcgg aaacgaggcc ggcccccggaaa gctgagcaaa

7441 gagtaactggg actgtctcgaa gggcaagaag agcaagcagc **INTRON7>** gtgagctccg

ggggcacgtg

7501 ggtccctccct gcgcggggct gagcggcttc ctggggcact gcgggttgcgtatcc

30 7561 cttctccctgt tttctctggc ctccgcattgg cttttggtaa ggctgtgcac aagctggggg

7621 ctctatggta tcggtcacca cctaattgca gagcctggct tgggtggcct ggagaggagg
7681 agggaaataag gctcccagtg ggaggctcat ggtaccagag tccctgtccac tgactccagt
7741 gtcctgtcca ctgactccag ttctctgc acttggccac tgcctgccc tctggacac
7801 cctcaatgtg aggaggcagc tggtgggtct taggtgggct gaggagaaaa gcagtcactg
5 7861 cagtacccgc acagagggca ctgcggggtc tctggagagg ctgctgcat gctgtggcca
7921 agtcagcagt gcactggggc gggcagggct ggctggccctt gggtgagagg ggacacctgg
7981 atggcaaact gatggaggct ggccttgcag **EXON8>** cgcccagagg caccacac
tgggagtta
8041 tccgggacat cctcatccac cggagacta acgagggcct catgaagtgg gagaatcgcc
10 8101 atgaaggcgt cttcaagttc ctgcgtccg aggctgtggc ccaactatgg ggccaaaaga
8161 aaaagaacag caacatgacc tacgagaagc tgagccggc catgag **INTRON8>** gtga
gctggcggcc
8221 aggaccctca cgatacagcc ggacatgggg acaggcgctc acactccac cgcctctt
8281 ctggctgcca cttggtttct tgcaacaggg ctgagtcctt agagtgagga caacatctgg
15 8341 gttggtctac ttcatggatt aaatgacaac atggagaaag tattagcctg gcagacagca
8401 gacacagtgc acttgagcta gcagcaacat ttctgtatc gcctgtgagg ctgtcctca
8461 ggaaggcacc tggagagtgg gaaagggggc aggagccgtg cccacccagg gcctggcitt
8521 ctccctcggt aagcacttag gttgttttc tctggcctc agttcctcc tgtgtccagg
8581 agtacactag atcatctaa gatccgtcc agccctaaaa tcatgtactt actttttttt
20 8641 tctttttctt tttaaatag aggcaagggt ctctacgttgc cccaggccgg tctcaaactc
8701 ctggcctcaa atgactctcc tgcctggcc tctcaaagtg ctgggattac aggtgtgagc
8761 caccgtgccc agctccctgg cttaaaagt catgtattt aatgatcaga ccccaagtcac
8821 agccatagga tacaaagaag caaaggcaaa gagccctgtg tccctggcac ggttacaggc
8881 cagtgttaggg aaagagcttc tgcttgccag tgtgaagaac agaggagttt aggaagtgtg
25 8941 agtcaggctc agcttagtca ggcagagacc agtgggcatg ggttacctgg ggttaacgcgc
9001 ggccaggtgg gcgggctggc agcctggggc ccatttcctg ccaaagcacc tctgaccatc
9061 ctctcttca cccag **EXON9>** gtact actacaaacg ggagatcctg gaacgggtgg
atggccggc
9121 actcgtctac aagttggca aaaactcaag cgcttggaaag gaggaagagg ttctccagag

-83-

9181 tcggaactga **END CDS** gggttggaac tataccggg accaaactca cggaccactc
 gaggcctgca
 9241 aacccctctg ggaggacagg caggccagat ggcccccaca ctggggaaatg ctcccagctg
 9301 tgctgtggag agaagctgat gttttgggtt attgtcagcc atcgctctgg gactcggaga
 5 9361 ctatggcctc gcctccccac cccctcttgc gaattacaag ccctggggtt tgaagctgac
 9421 tttatagctg caagtgtatc tccctttatc tggtgccctcc tcaaaccagg tctcagacac
 9481 taaatgcaga caacacccctc ctccgtcaga cacctggact gagccaaggaa ggcctggggaa
 9541 ggcccttaggg gagcaccgtg atggagagga cagagcaggg gctccagcac cttcttctg
 9601 gactggcggtt cacccctctg ctcaagtgcctt gggctccacg ggcaggggc agagcactcc
 10 9661 ctaatttatg tgcttatataa atatgtcaga tgtacataga gatctatttt ttctaaaaca
 9721 tccccctccc cactcctctc ccacagagtg ctggactgtt ccaggccctc cagtggctg
 9781 atgctggac ccttaggatg gggctccag ctcccttctc ctgtaatgg aggagagac
 9841 ctccaataaaa gtgccttctg ggctttttct a

SEQ ID NO:11 - 531bp GC3 DNA sequence isolated from modified RDA. GC3 is
 15 located within intron 7 and extends to exon 8 of the ELF3 gene between 7514
 to 8045 (using SEQ ID NO:1 numbering). The GC3 primers are in bold, the 202
 bp GC3 fragment amplified by GC3 primers are underlined.
 CCGGGCTGAGCGGCTTCCTGGGGCACTGCGGGTTGTCAGGTATCCCCTCTC
 CCGTTTCCCTCTGGCCTCCGCATGCCCTTGGTAAGGCTGTGCACAAGCTGGGG
 20 CTCTATGGTATCGGTACCAACCTAATTGCAGAGCCAGGCTGGTGGTGGCTGGAG
 AGGAGGAGGAAATAAGGCTCCAGTGGGAGGCTATGGTACCAAGAGTCCTGTC
CACTGACTCCAGTGTCCACTGACTCCAGTTCTCTGCACCTGGCCACT
GTCCTGCCCTCTGGTCACCCCTCAATGTGAGGAGGGCGCTGGTGGTCTTAGG
TGGGCTGAGGAGAAAAGCAGTCACTGCAGTACCCGCACAGAGGGCACTGCCGG
 25 GTCTCTGGAGAGGGCTTGCTGCATGCTGTGGCCAAGTCAAGCAGTGCACGTGG
 GCGGCAGGGCTGGCTGGCTGGCTGGGTGAGAGGGGGCACCTGGATGGCAAACGG
 ATGGAGGGCTGGCTTGCAGCGCCAGAGGCACCCACCTGTGGAGTTCATCCGG

SEQ ID NO:12 - 1002 bp unspliced mRNA of the ELF3 gene (from 6550 to 7551 of the ELF3 gene, using SEQ ID NO:1 numbering) in human breast tumor cell lines. The unspliced entire intron 4, intron 5, intron 6 and 5' portion of intron 7 are underlined. The intron/exon splice junction borders are in bold.

5 **GTTGGATCATTGAGCTGGAGAAGGATGGCATGGCCTTCCAGGAGGCCCTA**
GACCCAGGGCCCTTGTGAGAACCCTTTCTCCTCCTCCCCAGCCTGTCT****
TGTCCCATCCCTGCCCTCCACAGAGTGCTAGAGATGACCCCTCCCCAGACTT
CTTCCTCCCTCAATTAGAAAAATTGCAGCAGGTATCAGACCCATGGCAGCAT
CACCTGTCCTGGTCTGGTCCCTGAGCCCTCTGAGTTCTCACCTCCTTCCC

10 **AGACCAGGGCAGCCCTTGCCTAGGAGCTGGACGACGGTCAGCAAGCCA**
GCCCCTACCACCCGGCAGCTGGCGCAGGAGCCCCCTCCCTGGCAGCTCT
GACGTCTCCACCGCAGGTGAGAGCTCTCTGGGCCACAACCTCCCTCCCCG****
AAGTGTCCCTTGTCCCTCTGGCTCCAGCACCATAACTCAGGCCCTGTGGCAG
GAACAGGAACAGGCTGGGAAGTGTGTCTGAGAGCCAGCAGCGTGGTTGAACA

15 **GAAGGTGGGCCGGCAGGGGACTTACTCTGACCCGCC**AGGGACTGGT****
CTTCTCGGAGCTCCACTCCTCAGACTCCGGTGGAAAGTGACGTGGACCTGGATC
CCACTGATGGCAAGCTCTCCCCAGCGGTGAGTCGAGGGAGGTCCCCAAGAGG****
GCGTCCCATTAGCAATGCACAGGGGGCCGGCTTCTGCAGCCTTTCTG
TAGAGGGCTACTCTCCCTAACTCCCCTITGCCCTCCTGACCTTCCACCACC

20 **GTCCCCACAGATGGTTTCGTACTGCAAGAAGGGGATCCAAGCACGGAA**
GCGGAAACGAGGCCGGCCCCGAAAGCTGAGCAAAGAGTACTGGACTGTCTCG
AGGGCAAGAAGAGCAAGCACGGTGAGCTCCGGGGCACGTGGTCTCCCTG****
CGCCGGGCTGAGCGGCTTCCCTGGGGACTGCGGGTTTTG

SEQ ID NO:13 - An Alu_{kw} - the bold letters indicates a 17 bp sequence located
25 in the end of Alu sequence that repeats nucleotides 8746 to 8762 of ELF3
sequence

GTATGCTTGGCCCTTTCTTTCTCTCTCTCTTTATTTTGAGACAGGGTC
TCGCTCTGTACCCAGGTTAGAGTGCACTGGCACAATCTGGCTCGCTACAACC
TCTGCCTGCCGGGTCAAGTGATTCTGTGCCTCAGCCTCCAAGTAGCTGGGAT

TACAGGCACCTGCCACCATGCCAGCTAATTTGTATTTAGTAGAGACGGG
 GGTTTACCATGTTGGCTAGGCTGGTCTCGAACTCCTGACCTCAAGTGATCCGC
CCGCCTCAGCCTCCAAAGTGCTGGAATTACAGGTGTGAGCCA

SEQ ID NO:14 - An antisense insertion of a 315 bp Alu_{kwd} sequence in an ELF3 sequence. This sequence shows the ELF3 gene from nt 8685 to 9107 (numbering of SEQ ID NO:1) containing a 315 bp antisense insertion of the Alu_{kwd} sequence. Underlined letters represent the 315 bp Alu_{kwd} sequence, the bold letters indicates a 17 bp sequence located in the end of Alu_{kwd} sequence that repeats nt 8746 to 8762 of the ELF3 sequence. The bracketed numbers shows the insert point of the Alu_{kwd} in the ELF3 DNA sequence.

5 GGCCGGTCTCAAACTCCTGGCCTCAAATGACTCTCCTGCCTCGGCCTCTCAAAG
 TGCTGGGATTACAGGTGTGAGCCA[8762]GTATGCTTGGCCTTTCTTTTCTT
CTTCTTCTTTATTTTCGAGACAGGGCTCGCTCTGTCACCCAGGTTAGAGTG
CAGTGGCACAATCTGGCTCGCTACAACCTCTGCCTGCCGGGTTCAAGTGATT

10 TTGTGCCTCAGCCTCCAAGTAGCTGGGATTACAGGCACCTGCCACCATGCCAG
CTAATTTTGTATTTAGTAGAGACGGGGTTCACCATGTTGGCTAGGCTGG
TCTCGAACTCCTGACCTCAAGTGATCCGCCGCCTCAGCCTCCAAAGTGCTGG
AATTACAGGTGTGAGCCA[8763]CCGTGCCAGCTCCCTGGCCTAAAAGTCA

15 TGTAATTAATGATCAGACCCCAGTCACAGCCATAGGATACAAAGAAGCAAAGG
 20 CAAAGAGCCCTGTGCCTGGCACGGTTACAGGCCAGTGTAGGGAAAGAGCTT
 CTGCTTGCCAGTGTGAAGAACAGAGGAGTTAGGAAGTGAGTCAGGCTCAG
CTTAGTCAGGCAGAGACCAGTGGGATGGGTTACCTGGGGTAACGCGGGCCA
GGTGGGCGGGCTGGCAGCCTGGGGCCATTCCTGCCAAAGCACCTCTGACCA
TCCCTCTCTCACCCAGGTACTACTACAAACGGGAGATCCTGGAACGGG

25 **SEQ ID NO:15** - the sequence of the novel ELF3 5' UTR.
 ctccgccactccggtaggattccccgcgtcattccctagccagcttggaaactgcagaggggtccagagga
 ttgcagttctgaacctgcacactccagtcttagatctccgagcaagagcgttagcctc

-86-

SEQ ID NO:16 - GC3 sense primer - codons 7722-7741 of the ELF3 gene.

CCTGTCCACTGACTCCAGTG

SEQ ID NO:17 - GC3 antisense primer - codons 7923-7905 of the ELF3 gene.

ACTTGGGCCACAGCATGCAG

5 SEQ ID NO:18 - GC3 UPF antisense primer - codons 7572-7598 of the ELF3 gene.

ACCAAAGGCCATGCGGAGGCCAGAGAA

SEQ ID NO:19 - GC3 UPN antisense primer - codons 7523-7551 of the ELF3 gene.

10 CAACAACCCGGAGTGCCCCAGGAAGCCC

SEQ ID NO:20 - GC3 DF sense primer - codons 7943-7970 of the ELF3 gene.

GCAGGGCTGGCTGGCCTGGGTGAGAGG

SEQ ID NO:21 - GC3 DN sense primer - codons 8004-8030 of the ELF3 gene.

CTTGCAGCGCCAGAGGCACCCACCTG

15 SEQ ID NO:22 - GC3 (1-3) sense primer - codons 4819-4843 of the ELF3 gene.

GCTACCTGGCGGAAGTGGATTCTC

SEQ ID NO:23 - GC3 (1-3) antisense primer - codons 6240-6216 of the ELF3 gene.

CGCTTGCCTCGTACTTGTCTTCTC

20 SEQ ID NO:24 - GC3 (3-6) sense primer - codons 6180-6205 of the ELF3 gene.

AAGACGCAGGTTCTGGACTGGATCAG

-87-

SEQ ID NO:25 - GC3 (3-6) antisense primer - codons 7194-7171 of the ELF3 gene.

TGGGATCCAGGTCCACGTCACCTC

SEQ ID NO:26 - GC3 (6-8) sense primer - codons 7155-7179 of the ELF3 gene.

5 TCCTCAGACTCCGGTGGAAGTGACG

SEQ ID NO:27 - GC3 (6-8) antisense primer - codons 8109-8174 of the ELF3 gene.

CCGGCTCAGCTTCTCGTAGGTCATG

SEQ ID NO:28 - GC3 (8-9) sense primer - codons 8065-8089 of the ELF3 gene.

10 AGCTCAACGAGGGCCTCATGAAGTG

SEQ ID NO:29 - GC3 (8-9) antisense primer - codons 9352-9327 of the ELF3 gene.

TCCCAGGGACGATGGCTGACAATACAC

SEQ ID NO:30 - β -actin ES31 primer

15 CCCCAGCCATGTACGTTGCTATCC

SEQ ID NO:31 - β -actin ES33 primer

GCCTCAGGGCAGCGGAACCGCTCA

SEQ ID NO:32 - GC3DD sense primer - codons 8569-8596 of the ELF3 gene.

CCTGTGTCCAGGAGTACACTAGATCATC

20 SEQ ID NO:33 - INSE sense primer - codons 8659-8680 of the ELF3 gene.

AGAGGGCAAGGGTCTCTACGTTG

SEQ ID NO:34 - INSE antisense primer - codons 8774-8795 of the ELF3 gene.

TCCCTGGCCTAAAAGTCATGT

What is claimed is:

1. An isolated cDNA of a mammalian ELF3 gene, or fragment thereof at least 20 nucleotides long, comprising at least one intron of the ELF3 gene or a portion of an intron of the ELF3 gene.
- 5 2. The cDNA of claim 1, wherein the intron is selected from the group consisting of intron 4, intron 5, intron 6, intron 7, intron 8, and combinations thereof.
3. The cDNA of claim 1, wherein the intron is intron 4.
4. The cDNA of claim 3, wherein the intron 4 comprises SEQ ID NO:-5.
- 10 5. The cDNA of claim 1, wherein the intron is intron 5.
6. The cDNA of claim 5, wherein the intron 5 comprises SEQ ID NO:6.
7. The cDNA of claim 1, wherein the intron is intron 6.
8. The cDNA of claim 7, wherein the intron 6 comprises SEQ ID NO:7.
9. The cDNA of claim 1, wherein the intron is intron 7.
- 15 10. The cDNA of claim 1, wherein the intron 7 comprises SEQ ID NO:8.
11. The cDNA of claim 1, wherein the intron is intron 8.
12. The cDNA of claim 1, wherein the intron 8 comprises SEQ ID NO:9.

-90-

13. The cDNA of claim 1, wherein the cDNA also comprises SEQ ID NO:13.

14. The cDNA of claim 13, wherein the SEQ ID NO:13 is within intron 8.

15. The cDNA of claim 14, wherein the SEQ ID NO:13 is between 5 nucleotides 8762 and 8763 using the numbering of SEQ ID NO:1.

16. The cDNA of claim 1, comprising SEQ ID NO:11.

17. The cDNA of any one of claims 1-16, wherein the ELF3 gene comprises a nucleotide sequence encoding the amino acid sequence of SEQ ID NO:3 or SEQ ID NO:4.

10 18. The cDNA of any one of claims 1-17, wherein the cDNA comprises the entire ELF3 gene coding region.

19. The cDNA of claim 1, comprising introns 4, 5, 6 and 7 of the ELF3 gene.

15 20. The cDNA of any one of claims 1-19, wherein the ELF3 gene comprises the nucleotide sequence of SEQ ID NO:15.

21. The cDNA of claim 20, comprising SEQ ID NO:2, wherein the cDNA may be interspersed by one or more introns.

22. The cDNA of any one of claims 1-21, wherein the cDNA was prepared from a composition comprising a cell, wherein the cell further 20 comprises genomic DNA comprising an Alu_{kwd}, wherein the Alu_{kwd} consists of SEQ ID NO:13.

23. The cDNA of claim 22, wherein the Alu_{kwd} is between nucleotides 8762 and 8763 of an ELF3 gene in the cell.

24. The cDNA of any one of claims 1-23, wherein the cDNA was prepared from a composition comprising a cell, the cell obtained from a human patient being tested for breast cancer.

25. The cDNA of claim 24, wherein the patient is at high risk for breast cancer.

26. The cDNA of any one of claims 22-25, wherein the cell is a peripheral blood mononuclear cell.

10 27. The cDNA of any one of claims 22-25, wherein the cell was obtained from a tissue biopsy.

28. The cDNA of claim 27, wherein the tissue biopsy was a breast tissue biopsy.

15 29. The cDNA of any one of claims 1-28, wherein the cDNA was prepared using RT-PCR.

30. The cDNA of claim 29, wherein the cDNA was amplified using primers that are suitable for amplifying at least a portion of intron 4 of the ELF3 gene.

20 31. The cDNA of claim 29, wherein the cDNA was amplified using primers that are suitable for amplifying at least a portion of intron 5 of the ELF3 gene.

32. The cDNA of claim 29, wherein the cDNA was amplified using primers that are suitable for amplifying at least a portion of intron 6 of the ELF3 gene.

33. The cDNA of claim 29, wherein the cDNA was amplified using 5 primers that are suitable for amplifying at least a portion of intron 7 of the ELF3 gene.

34. A vector comprising the cDNA of any one of claims 1-33.

35. A cell transfected with the vector of claim 34.

36. The cell of claim 35, wherein the cell is a prokaryote.

10 37. The cell of claim 35, wherein the cell is a eukaryote.

38. The cell of claim 35, wherein the vector sequence comprising the cDNA is integrated into a chromosome of the cell.

39. The cell of claim 35, wherein the vector autonomously replicates in the cell.

15 40. The cell of any one of claims 35-39, wherein the cDNA comprises the entire ELF3 gene coding region.

41. A set of two primers, each less than 30 nucleotides in length, wherein each primer is homologous to a portion of an ELF3 gene, and (a) wherein at least one primer is homologous to a portion of an intron of the ELF3 20 gene or (b) wherein each primer is homologous to a portion of different exons of the ELF3 gene.

-93-

42. The set of two primers of claim 41, wherein the intron of the ELF3 gene is selected from the group consisting of intron 4, intron 5, intron 6, intron 7 and intron 8.

43. The set of two primers of claim 41, wherein the intron of the ELF3 gene is intron 8.

44. The set of two primers of claim 43, wherein one of the two primers is homologous to a region of an ELF3 gene 5' to nt8762 of the ELF3 gene, and the other of the two primers is homologous to a region of the ELF3 gene 3' to nt 8763 of the ELF3 gene.

10 45. A set of two primers, each less than 30 nucleotides in length, wherein at least one primer is at least 95% homologous to SEQ ID NO:13.

46. The set of two primers of claim 45, wherein both primers are at least 95% homologous to SEQ ID NO:13.

15 47. The set of two primers of claim 45, wherein both primers are homologous to SEQ ID NO:13.

48. The set of two primers of claim 45, wherein one primer is homologous to SEQ ID NO:13 and the other primer is homologous to a portion of an ELF3 gene.

20 49. The set of two primers of claim 45, wherein one primer is homologous to SEQ ID NO:13 and the other primer is homologous to an intron of an ELF3 gene.

-94-

50. The set of two primers of claim 49, wherein the other primer is homologous to intron 8 of the ELF3 gene.

51. A set of two primers, each less than 30 nt in length, wherein the set of primers is suitable for amplifying an ELF3 5' UTR that is at least 95% homologous to SEQ ID NO:15.

52. The set of two primers of claim 51, wherein one primer is homologous to SEQ ID NO:15 and the other primer is homologous to an ELF3 gene.

53. An isolated nucleic acid or mimetic between about 20 nucleotides and about 5,000 nucleotides long comprising a sequence homologous to at least a portion of an intron of a human ELF3 gene.

54. The isolated nucleic acid or mimetic of claim 53, wherein the intron of the human ELF3 gene is selected from the group consisting of intron 4, intron 5, intron 6, intron 7 and intron 8.

55. The isolated nucleic acid or mimetic of claim 53, wherein the intron is intron 4.

56. The isolated nucleic acid or mimetic of claim 55, wherein the sequence comprises an entire intron 4 or its complement.

57. The isolated nucleic acid or mimetic of claim 53, wherein the intron is intron 5.

58. The isolated nucleic acid or mimetic of claim 57, wherein the sequence comprises an entire intron 5 or its complement.

-95-

59. The isolated nucleic acid or mimetic of claim 53, wherein the intron is intron 6.

60. The isolated nucleic acid or mimetic of claim 59, wherein the sequence comprises an entire intron 6 or its complement.

5 61. The isolated nucleic acid or mimetic of claim 53, wherein the intron is intron 7.

62. The isolated nucleic acid or mimetic of claim 61, wherein the sequence comprises an entire intron 7 or its complement.

10 63. An isolated nucleic acid or mimetic between about 20 nucleotides and about 5000 nucleotides long comprising a sequence at least 95% homologous to SEQ ID NO:13 or its complement.

64. The isolated nucleic acid or mimetic of claim 63, wherein the sequence is homologous to at least 50 nucleotides of SEQ ID NO:13.

15 65. The isolated nucleic acid or mimetic of claim 63, wherein the sequence is homologous to the entire SEQ ID NO:13.

66. The isolated nucleic acid or mimetic of claim 63, wherein the sequence further comprises a second sequence homologous to at least 10 consecutive nucleotides of SEQ ID NO:10 or its complement.

20 67. The isolated nucleic acid or mimetic of claim 66, wherein the second sequence is homologous to at least 10 consecutive nucleotides of SEQ ID NO:9 or its complement.

-96-

68. The isolated nucleic acid or mimetic of claim 66, wherein the second sequence is homologous to at least 10 consecutive nucleotides immediately 5' to nucleotide 8763, or immediately 3' to nucleotide 8762 of the ELF3 gene, using the ELF3 gene sequence numbering of SEQ ID NO:1.

5 69. The isolated nucleic acid or mimetic of claim 63, comprising a nucleotide sequence homologous to at least nucleotides 8752 to 8773 of SEQ ID NO: 1, with SEQ ID NO:13 inserted between nucleotides 8762 and 8763.

10 70. An isolated nucleic acid or mimetic between about 20 nucleotides and about 5000 nucleotides long comprising a nucleotide or mimetic sequence at least 95% homologous to SEQ ID NO:15.

71. The isolated nucleic acid or mimetic of claim 70, wherein the nucleotide or mimetic sequence is homologous to SEQ ID NO:15.

15 72. The isolated nucleic acid or mimetic of claim 70 or 71, further comprising at least 20 nucleotides or mimetics of the 5' end of a sequence encoding SEQ ID NO:3 or SEQ ID NO:4 or its complement adjoining the 3' end of the nucleotide sequence.

73. The isolated nucleic acid or mimetic of any one of claims 53-72, wherein the nucleotide or mimetic sequence is DNA.

20 74. The isolated nucleic acid or mimetic of any one of claims 53-72, wherein the nucleotide or mimetic sequence is RNA.

75. The isolated nucleic acid or mimetic of any one of claims 53-74, wherein the sequence is less than 2000 nucleotides long.

-97-

76. The isolated nucleic acid or mimetic of any one of claims 53-74, wherein the sequence is less than 1000 nucleotides long.

77. The isolated nucleic acid or mimetic of any one of claims 53-74, wherein the sequence is less than 500 nucleotides long.

5 78. The isolated nucleic acid or mimetic of any one of claims 53-74, wherein the sequence is less than 200 nucleotides long.

79. The isolated nucleic acid or mimetic of any one of claims 53-74, wherein the sequence is less than 100 nucleotides long.

10 80. The isolated nucleic acid or mimetic of any one of claims 53-74, wherein the sequence is more than 100 nucleotides long.

81. The isolated nucleic acid or mimetic of any one of claims 53-74, wherein the sequence is more than 200 nucleotides long.

82. The isolated nucleic acid or mimetic of any one of claims 53-74, wherein the sequence is more than 500 nucleotides long.

15 83. The isolated nucleic acid or mimetic of any one of claims 53-74, wherein the sequence is more than 1000 nucleotides long.

84. A vector comprising the sequence of any one of claims 53-83.

85. A cell comprising the vector of claim 84.

86. A probe comprising the isolated nucleic acid or mimetic of any one
20 of claims 53-83, the probe further comprising a detectable label.

87. The probe of claim 86, wherein the detectable label is fluorescent or radioactive.

88. A pair of cell cultures, where each cell culture is of the same tissue type and is derived from a biopsy of cancerous mammalian tissue, and where 5 one of the cell lines is of cancerous cells and the other cell line is of matched noncancerous cells.

89. The pair of cell cultures of claim 88, wherein the mammalian tissue is breast tissue.

90. The pair of cell cultures of claim 88 or 89, wherein the cells are
10 myofibroblast cells or CD4+ lymphocytes.

91. A method for determining whether a patient has cancer or is at risk for cancer, the method comprising evaluating whether a cell in the patient comprises a nucleic acid sequence selected from the group consisting of an ELF3 mRNA retaining at least a portion of an intron, a sequence at least 95% homologous to SEQ ID NO: 15, and an Alu_{kwd}, wherein a patient comprising at least one of those sequences has cancer or is at risk for cancer.,

92. The method of claim 91, wherein the sequence is **ELF3 mRNA** retaining at least a portion of an intron.

93. The method of claim 91, wherein the sequence is SEQ ID NO:15.

94. The method of claim 91, wherein the sequence is Alu_{kwd}.

95. The method of claim 94, wherein the sequence is SEQ ID NO:13.

-99-

96. The method of any one of claims 91-95, the method further comprising a polymerase chain reaction.

97. The method of claim 96, wherein the method comprises reverse transcriptase-polymerase chain reaction.

5 98. The method of any one of claims 91-95, the method further comprising a northern hybridization or a Southern hybridization.

99. The method of any one of claims 91-95, the method further comprising sequencing the nucleic acid sequence.

100. The method of any one of claims 91-99, wherein the cell is a
10 PBMC.

101. The method of any one of claims 91-99, wherein the cell is from a tissue biopsy.

102. The method of claim 101, wherein the tissue is breast tissue.

103. The method of claim 101 or 102, wherein the cell is from a tissue
15 effusion.

104. A kit for evaluating whether a patient has cancer or is at risk for cancer, the kit comprising

a. the set of two primers of any one of claims 41-52, and
b. instructions directing the use of the primers for determining
20 whether a portion of the ELF3 gene amplified by the two primers is present in a nucleic acid preparation.

5 wherein the two primers are homologous to portions of the ELF3 gene, or its complement, that flank an intron of the ELF3 gene.

106. The kit of claim 105, wherein the intron of the ELF3 gene is selected from the group consisting of intron 4, intron 5, intron 6, intron 7 and intron 8.

10 107. The kit of claim 105, wherein the intron of the ELF3 gene is intron 8.

108. The kit of claim 107, wherein one of the two primers is homologous to a region of an ELF3 gene 5' to nt 8762 of the ELF3 gene or its complement, and the other of the two primers is homologous to a region of the 15 ELF3 gene 3' to nt 8763 of the ELF3 gene or its complement.

109. A kit for evaluating whether a patient has cancer or is at risk for cancer, the kit comprising

- a. at least one of
 - i. the isolated nucleic acid or mimetics of any one of claims 20 53-83, or
 - ii. the probe of claim 86 or 87; and
 - b. instructions directing the use of the nucleic acid or mimetic for determining whether a nucleic acid sequence homologous to the probe is present in a sample from the patient.

-101-

110. The kit of claim 109, wherein the isolated nucleic acid or mimetic is on a gene chip.

111. The kit of claim 109 or 110, further comprising instructions to sequence any nucleic acid sequence homologous to the probe that is present in 5 the sample from the patient.

112. A method for determining whether a cell or a sample comprises a virus, the method comprising

(a) adding contents of the cell or the sample to a culture, where the culture comprises a susceptible cell that is capable of acquiring a 10 characteristic upon infection with a virus, the characteristic selected from the group consisting of intron retention of ELF-3 mRNA, and acquisition of SEQ ID NO:13 in an ELF3 gene; and

b. subsequently determining whether a susceptible cell has acquired the characteristic after addition of the contents of the cell.

15 113. The method of claim 112, wherein the characteristic is intron retention of ELF-3 mRNA.

114. The method of claim 112, wherein the characteristic is acquisition of SEQ ID NO:13 in an ELF3 gene.


20 115. The method of any one of claims 112-114, wherein the susceptible cell is a BJAB cell.

-102-

Abstract


ELF3 gene compositions associated with cancer are provided, including ELF3 mRNA intron retention, a novel ELF3 5' untranslated region, and a novel Alu, Alu_{kw}. Methods and kits using primers or probes to detect the presence of 5 these ELF3 gene compositions are also provided. Methods for determining whether a cell comprises a virus are also provided.

FIG. 1



A

$\frac{T\ N}{Msp\ I}$ $\frac{T\ N}{Hpa\ II}$



B

$\frac{N\ T}{Hpa\ II}$ $\frac{N\ T}{Msp\ I}$

FIG. 2




FIG. 3




FIG. 4




FIG. 5



202bp GC3



396bp b-actin

M D R N P

FIG. 6




FIG. 7




FIG. 8




FIG. 9




FIG. 10




FIG. 11




FIG. 12




FIG. 13




FIG. 14




FIG. 15




FIG. 16




FIG. 17




FIG. 18





FIG. 19



**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.